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Liver development at the postnatal age has been understudied despite being a time when
the liver is rapidly growing and changing its primary function as an organ involved in
hematopoiesis to an organ responsible for metabolism. Long non-coding RNAs (LncRNAs) are
important in many biological processes, including organogenesis, normal liver functions, and
liver diseases. Expression levels of lncRNAs change in identifiable patterns in liver during
development, and H19, due to its expression pattern, may be important for liver development.
H19 RNA is highly expressed at early postnatal ages and precipitously decreases at a
specific time corresponding with increases in expression of genes important for mature liver
function, such as drug metabolizing enzymes. H19’s role in the regulation of liver maturation is
currently unknown. Using an H19 knockout mouse model to determine the role of H19 in liver
development, we quantified gene expression for insulin growth factor signaling, Wnt signaling,
key cytochrome P450 (P450) enzymes known to change as the liver develops, and fetal and adult
plasma protein produced in liver. In mice lacking H19 expression, liver weights were
significantly increased immediately after birth and significant increases were found in the
number of actively proliferating cells. Increases in cell proliferation may be due to increases in
β-catenin protein affecting Wnt signaling, increases in insulin-like growth factor 2 (IGF2)
expression, and/or increases in insulin-like growth factor 1 receptor (IGF1R) expression at the
protein level. Loss of targeted inhibition of IGF1R by microRNA 675 (miR-675) may be the
cause of IGF1R increases, as miR-675 expression is also abrogated with loss of H19 expression
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in our model. P450 expression patterns were significantly altered for certain P450 genes at
particular time points in development, but were largely unchanged. No change in the production
of plasma proteins was found, indicating H19 may not be important for liver maturation despite
its role in controlling cell proliferation during liver growth. H19 may be important for normal
liver development, and understanding how the liver matures will assist in predicting drug
efficacy and toxicity in pediatric populations.
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Chapter 1: Introduction/Literature Review
1.1 Liver Development
Liver development requires specific temporal molecular events leading to the generation
of each specific cell type, and the formation of a precise three-dimensional architecture. In
mammals, the liver forms one cell thick cords of polarized hepatocytes. Hepatocytes secrete
hormones into the blood from their basolateral surface, and they secrete bile acids and bile salts
across their apical surface into tight junctions that form canaliculus surrounding each hepatocyte
(Si-Tayeb et al., 2010). The liver lobes are distinctively arranged containing one centrilobular
vein at the lobe center and the portal triad consisting of the hepatic artery, portal vein, and one or
two bile ducts (Mescher and Junqueira, 2013). The hepatic artery supplies blood from the heart
and the portal vein supplies blood from the gastrointestinal tract, gallbladder, pancreas, and
spleen. Blood leaves the liver to return to the heart via the centrilobular vein. The axis between
the portal triad and the centrilobular vein separates liver cells into distinct zones. Zone 1
contains oxygen rich cells near the portal triad, zone 3 contains cells near the centrilobular vein,
and zone 2 is comprised of cells in-between. Cell function and gene expression exhibit different
patterns depending on zonal location. For example, the metabolism of xenobiotics mainly occurs
in hepatocytes closer to the centrilobular vein in zone 2 and zone 3 while gluconeogenesis occurs
more in the periportal region in zone 1. Canonical Wnt signaling plays a key role in maintaining
hepatocyte zonation in mice (Monga and SpringerLink (Online service), 2011).
Liver ontogenesis is complex and tightly orchestrated. Hepatocytes and biliary epithelial
cells are formed from the endoderm germ layer in the embryo. Stromal cells, stellate cells,
Kuppfer cells, and blood vessels are derived from the mesoderm. In mice, the endoderm forms
around embryonic days 6.5 to 7.5 and by embryonic day 15, hepatoblasts are formed which will
1

eventually differentiate into hepatocytes and biliary cells (Zorn, 2008). Prior to hepatoblast
formation, the endoderm cells near the sinus venosus become columnar and begin to express
genes indicating hepatic cell fate at embryonic day 8.5 (Bort et al., 2006). The initiation of liver
ontogeny is when epithelial cells of the foregut endoderm commit to becoming the liver
primordium at around embryonic day nine (Hata et al., 2007). And, after embryonic day 9.5, the
matrix on the basal surface of the endoderm near the sinus venosus degrades, and hepatoblast
cords migrate into the surrounding stroma (Bort et al., 2006). Between embryonic days 10 to 15
the liver becomes the major hematopoietic organ in the fetus (Zorn, 2008) and throughout
ontogenesis until it is fully mature, gene expression profiles change in identifiable patterns (Li et
al., 2009a).
Wnt signaling plays important roles in proper fetal liver organogenesis. Acting to repress
Hhex in the posterior endoderm during early somite stages, Wnt signaling prevents ectopic
hepatic development. Repression of Wnt signaling allows Hhex expression in the anterior
endoderm, allowing liver formation. After hepatic specification, Wnt signaling acts in the
opposite manner to promote hepatogenesis (McLin et al., 2007). In rats, Wnt2 increases
proliferation of sinusoidal endothelial cells by targeting VEGF receptor-2 (Klein et al., 2008),
and activation of the VEGF receptor in mice results in sinusoidal endothelial cell secretion of
mitogenic factors increasing hepatocyte proliferation and liver mass (LeCouter et al., 2003).
Wnt signaling also promotes stem cell specification to cholangiocytes in embryonic mouse liver
cultured ex vivo (Hussain et al., 2004). Before birth, this pathway clearly acts to instruct liver
development, and after birth, as the liver continues to grow and mature, Wnt signaling remains a
key factor.
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Wnt signaling is important for postnatal liver growth and maturation. ß-Catenin has been
shown to be critical for early postnatal liver growth, as knockout results in a reduction in cell
proliferation (Apte et al., 2007). Aside from growth, Wnt signaling impacts normal liver
functions including affecting expression of drug metabolizing enzymes and influencing bile acid
homeostasis. For example, ß-catenin activates P450s (Loeppen et al., 2005), and knockout of ßcatenin results in lower expression of P450s (Sekine et al., 2006). ß-Catenin knockout mice
exhibit a decrease in bile flow and mild intrahepatic cholestasis with an inability to respond to
increases in bile acids (Yeh et al., 2010). Acting before and after birth, Wnt signaling directs
proper liver growth and maturation.
Insulin-like growth factor (IGF) signaling is important for proper development. IGF
signaling is due to two ligands, IGF1 and IGF2, capable of activating receptors, IGF1R and
IGF2R. IGF1R responds to both ligands, while IGF2R only responds to IGF2. Growth hormone
from the pituitary stimulates the liver to release IGF, and binding to the tyrosine kinase receptor,
IGF1R, results in receptor autophoshorylation activating phosphorylation of various intracellular
substrates. Positive signaling requires IGF binding to IGF1R, but IGF2 binding to IGF2R serves
to limit IGF2 to dampen positive signaling (Baker et al., 1993). Most tissue in human and mouse
express IGF1R and respond to each isoform of IGF, which are dominantly expressed at different
stages of liver development. Human and mouse livers express IGF2 early in life, and levels
decline as the liver matures. IGF1 exhibits the opposite expression, and is not highly expressed
until the liver is fully mature. Therefore, IGF2 has been described as a fetal growth factor while
IGF1 is considered an adult growth factor. Mouse knockout studies have elucidated the
influence of IGF1, IGF2, and IGF1R on total body weight indicating IGF signaling is important
for normal growth. Disruption of either IGF1 or IGF2 in mice results in a reduction in total body
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weight to 60% of normal weight at embryonic day 18.5. Disruption of IGF1R expression has an
even more dramatic impact on total body weight. Mice embryonic day 18.5 are only 40%
normal wild type weight (Baker et al., 1993).
Hematopoiesis occurs in site specific locations depending on the stage of development.
Prior to liver formation, hematopoiesis occurs in the aorta-gonad-mesonephros region in the
embryonic mesoderm. Here, oncostatin M acts to stimulate development of both hematopoietic
cells and endothelial cells. After the liver begins to form, it accepts hematopoietic stem cells and
begins to function to support the production (erythropoiesis) and decomposition of red blood
cells. Fetal liver is the major hematopoietic organ in the body before birth. Hematopoietic cells
of the liver produce oncostatin M, and this promotes liver maturation through differentiation
(Miyajima et al., 2000). After the liver gains maturity, the differentiated cells are no longer able
to support hematopoiesis, and the formation of blood stem cells shifts from being produced in
liver to being produced in bone marrow. However, after this switch, the liver continues to be
important for blood functions producing plasma proteins including albumin, the most abundant
protein in blood serum, and coagulation factors. Liver also filters the blood and metabolizes
various compounds included unneeded hormones and harmful chemicals.
A major function of the liver is to metabolize endogenous and exogenous compounds to
be cleared by the body so they do not accumulate and reach potentially toxic levels. Exogenous
compounds such as xenobiotics are metabolized by P450s, and expression of specific P450s
depends on the maturity of the liver. Certain isoforms of different P450s are expressed before
life and early life while other forms are present only in fully mature adult liver. For example, in
mice, CYP3A11 is not highly expressed before or immediately following birth. CYP3A11
gradually increases in expression as the liver matures. Opposite to this, CYP3A16 is only highly
4

expressed in fetal and early postnatal livers of mice (Peng et al., 2012). Similarly in human, the
major CYP3A isoform is CYP3A4 in the adult liver, but during early liver development,
CYP3A7 is the dominate CYP3A isoform (Lacroix et al., 1997). The major CYP3A isoform
expressed depends on the stage of development of the liver. CYP2C29 and CYP2B10 are
important xenobiotic metabolizing P450s that also exhibit a distinct pattern of expression during
liver development. CYP2C29 is not highly expressed until the adult ages, while CYP2B10
expression is at its highest during the postnatal adolescent stage (Peng et al., 2012). Comparing
the normal pattern of expression of well-characterized P450s to experimental conditions can
allow for the determination of proper liver development.
Another function of liver is production of serum proteins which bind cations, fatty acids,
and bilirubin. Two serum proteins, albumin and α-fetoprotein are produced at different levels
during liver maturation, and comparing their patterns of expression in experimental conditions
may allow examination of changes in proper liver development. In human, α-fetoprotein serum
levels are high only in the embryo and fetus and drop to low levels after birth. Human albumin
serum levels rise from low expression in the fetus to high expression in adult, but are always
expressed at a higher level than α-fetoprotein even in early development (Nayak and Mital,
1977). Albumin functions as the main protein in blood to regulate oncotic pressure, however, the
function of α-fetoprotein is less clear, despite being heavily expressed in fetal liver.
1.2 Long Non-Coding RNA in Liver Development
Long non-coding RNA (LncRNA) are transcripts greater than 200 nucleotides that do not
code for protein. Despite not being translated, approximately 35,000 lncRNAs have been
discovered as of 2005. LncRNAs exhibit characteristics of mRNA such as being 5’ capped,
spliced, and poly-adenylated (Carninci et al., 2005). LncRNAs are also generated similarly to
5

proteins having similar histone-modification profiles, splicing signals, and exon and intron
lengths (Derrien et al., 2012). LncRNAs are highly abundant comprising 80% of all
transcription (Kapranov et al., 2007), and their expression levels are highly tissue specific
(Derrien et al., 2012) indicating their potential importance in regulating cell differentiation.
Many lncRNAs have been discovered as being regulators of gene expression. For
example, HOTAIR binds to histone modification complexes including Polycomb Repressive
Complex 2 (PRC2) capable of repressing transcription of the HOXD locus through epigenetic
modification (Tsai et al., 2010). And XIST, one of the first characterized lncRNAs capable of
manipulating gene expression, inactivates an X-chromosome in female placental mammals
controlling gene dosage between XY males and XX females by first accumulating on the
chromosome followed by recruitment of PRC1 and PRC2 leading to epigenetic gene silencing
(Wutz and Gribnau, 2007). LncRNAs have also been implicated in more broad biologically
relevant functions including controlling cell lineages by maintenance of stem cell quiescence
(Venkatraman et al., 2013), pluripotency (Fatica and Bozzoni, 2014), and differentiation (Fatica
and Bozzoni, 2014). This section highlights liver lncRNAs and their importance in normal
development, normal liver functions, and in disease states as well as describes the various
molecular mechanisms liver lncRNAs use to achieve their biological function.
LncRNAs are important regulators of normal liver development. LncRNAs are
differentially expressed throughout different stages of development, and our laboratory has
previously characterized, using whole transcriptome analysis, the expression of liver lncRNAs
by RNA-sequencing in mice before birth to adult (Peng et al., 2014). We have discovered that
there are three major oncogenic patterns of differential expression that occur at the neonatal,
adolescent, and adult stages indicating differential lncRNA expression highlighting their
6

important role in growth and development. Another lab has done similar work to characterize
mouse liver transcriptomes during development. They examined mouse livers at embryonic days
14.5 and 18 as well as adult livers, and have found similar results indicating that lncRNA
expression is temporal and exists in patterns throughout development (Lv et al., 2014). For
example, as the liver ages, changes in transcription of lncRNAs occurs. In mice, it was
discovered lncRNAs MEG3, RIAN, and MIRG all increased in mice aged 28 months compared
to young adults, four months old (White et al., 2015). Differences in lncRNA expression is not
limited to different developmental stages. Many liver lncRNAs are differentially expressed due
to growth hormone regulation. This results in sex-biased expression of lncRNAs (Melia et al.,
2015). Liver lncRNAs may be important in regulating different developmental programs in liver
due to having precise timing in their expression at particular stages during development.
1.3 Long Non-Coding RNA in Liver Functions
1.3.1 LncRNAs in Hematopoiesis
LncRNAs have been shown to play important roles in hematopoiesis. Erythropoiesis is
regulated by the survival of red blood cell lineage-committed precursors and lincRNA-EPS has
been shown to inhibit the apoptosis of red blood cell precursors in fetal liver (Paralkar and
Weiss, 2011). There is a balance between the inhibition and promotion of apoptosis in this
lineage. Erythropoietin, the major erythropoietic cytokine, binds the Epo receptor initiating
signaling pathways that inhibit apoptosis of erythroid precursors (Paralkar and Weiss, 2011),
while signal transduction through Fas and tumor necrosis factor receptors promotes apoptosis.
LincRNA-EPS was shown to promote erythropoiesis through the prevention of apoptosis of red
blood cell precursors by potentially binding Pycard to inhibit its transcription by recruiting
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transcriptional repressor complexes (Paralkar and Weiss, 2011). PYCARD normally activates
caspases to induce apoptosis, but is inactive leading to lineage progression.
MALAT1 is another lncRNA that controls lineage progression in hematopoiesis.
MALAT1 expression is high in early-stage progenitor cells, and low in late-stage progenitor
cells. Knockdown of MALAT1 inhibits erythroid myeloid lymphoid cell (a mouse multipotent
hematopoietic cell line) proliferation after the tumor suppressor, p53, binds to the Malat1
promoter to repress its transcription (Ma et al., 2015). MALAT1 is also a good example of a
lncRNA having multiple functions. MALAT1 plays roles in liver regeneration (Li et al., 2017),
glucose homeostasis, liver fibrosis (Yu et al., 2015a), HCC, and can be used as a predictive
biomarker for disease in humans (Konishi et al., 2015). LncRNAs controlling differentiation
have been widely reported in literature for various cell types and organs, including the liver.
1.3.2 LncRNAs in Lipid Metabolism and Homeostasis
Metabolism of endogenous compounds is also an important function of liver, and there
have been many studies examining the roles of lncRNAs in lipid metabolism and lipid
homeostasis with a focus on disease states regarding lipid metabolism disorder. Fatty acids,
including the most common non-toxic form, triacylglycerols, are the most commonly stored and
circulating forms of energy. The liver is the hub of fatty acids synthesis, lipogenesis, and lipid
circulation (Nguyen et al., 2008). Improper lipid homeostasis can result in diseases, including
metabolic syndromes such as obesity and type 2 diabetes.
LncLSTR has been shown to be a regulator of triglycerides by interacting with TDP-43, a
transcriptional suppressor of CYP8B1 expression. This interaction leads to increased CYP8B1
activity, resulting in changes in bile acid ratios which induce apolipoprotein C2 expression
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through FXR. Increased apolipoprotein C2 leads to lipoprotein lipase activation and increased
plasma triglyceride clearance (Li et al., 2015b).
Lnc-HC regulates cholesterol metabolism by forming a complex with hnRNPA2B1 (Lan
et al., 2015). This protein-RNA complex then binds to CYP7A1 and ABCA1 mRNA inhibiting
their expression. CYP7A1 and ABCA1 are implicated in cellular cholesterol excretion, so when
the level of lnc-HC is increased, a risk for cholesterol disorder is also increased. Furthermore,
high cholesterol upregulates lnc-HC expression through the activator C/EBPß (Lan et al., 2015).
1.3.3 LncRNAs in Liver Regeneration
Aside from normal hepatic growth during development, the liver also has the ability to
grow after injury after either physical (surgical removal) or chemical (hepatotoxicity) insult
(Michalopoulos and DeFrances, 1997). This is a remarkable ability owing to being the only
visceral organ capable of regeneration and needing only as little as 33% normal tissue for regrowth to its original mass with minimal disturbance in liver functions such as glucose
regulation, blood protein synthesis, bile synthesis, and drug metabolism (Michalopoulos and
DeFrances, 1997).
Activation of the cell cycle is needed for liver regeneration. To replace injured tissue, the
organ needs to participate in massive cell-division. Two lncRNAs have been proven to be
important in this process both using the same mechanism to activate the cell cycle. LncRNALALR1 (Xu et al., 2013) and MALAT1 (Li et al., 2017) enhance cell proliferation during liver
regeneration by activation of Wnt/ß-catenin signaling facilitating the expression of cyclin D1
through suppression of Axin1. Mechanistically, lncRNA-LALR1 suppresses expression of
Axin1 by recruiting CTCF to its promoter (Xu et al., 2013).
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1.4 Long Non-Coding RNA in Liver Diseases
1.4.1 LncRNAs in Glucose Homeostasis
Glucose homeostasis is an important function of liver and is influenced by lncRNA
regulation. Many lncRNAs have been implicated in controlling glucose homeostasis (Sun and
Wong, 2016). In particular, the previously discussed MALAT1 also appears to influence the
pathogenesis of diabetes. MALAT1 is upregulated in diabetic rat and mice models and
participates in crosstalk with the p38 MAPK signaling pathway regulating endothelial cell
function (Liu et al., 2014). Another multifunctional lncRNA, MEG3, is most often studied for its
role in cancer (Anwar et al., 2012; Zhuo et al., 2016), but has been shown to enhance insulin
resistance in type 2 diabetes (Zhu et al., 2016). MEG3 increases FOXO1 expression, and
FOXO1 is associated with characteristics of type 2 diabetes including hyperglycemia and
hypertriglyceridemia. MEG3 is a well-studied lncRNA also having been studied in multiple
liver diseases and disorders including fibrosis (He et al., 2014).
1.4.2 LncRNAs in Liver Fibrosis, Fatty Liver Diseases
Many lncRNAs work in tandem to regulate liver fibrosis. For example, lincRNA-p21
inhibits the activation, proliferation, and cell cycle progression of stellate cells to reduce fibrosis
and is decreased in patients with fibrosis and cirrhosis (Zheng et al., 2015), and MALAT1 is
upregulated in liver fibrosis acting as a competing endogenous RNA for miR-101b which
normally represses RAC1 leading to an increase in stellate cell proliferation, activation, and
progression of the cell cycle (Yu et al., 2015a).
H19 was recently implicated in being important in bile acid homeostasis. Bile is
produced in liver and functions to aid digestion of lipids by emulsification in the small intestine.
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Cholestatic liver fibrosis can occur after small heterodimer partner (SHP) degradation by BCL2,
an antiapoptotic regulator protein. SHP normally acts to transcriptionally repress H19, and H19
is not found in normal healthy adult liver. If H19 not repressed, liver injury, fibrosis, and
inflammation occurs alongside an increase in serum bile acids and bilirubin (Zhang et al., 2016).
Another lncRNA, HULC, is upregulated in HCC and promotes lipogenesis to increase
triglyceride and cholesterol levels in cancer cells. HULC activates PPARA by inhibiting
expression of miR-9, an inhibitory microRNA against PPARA mRNA. PPAR activates the
ACSL1 promoter when not inhibited due to HULC coordinating methylation of the miR-9
promoter. ACSL1 generates cholesterol which further promotes HULC’s ability through
positive feedback (Cui et al., 2015).
Specific lncRNAs implicated in liver fibrosis have been shown to affect the profibrogenic
factor TGF-β1 (Yang et al., 2015; Yu et al., 2015b). APTR is increased in the stellate cells of
fibrotic liver, and APTR promotes upregulation of α-smooth muscle actin in stellate cells
through TGF-β1 signaling (Yu et al., 2015b). TGF-β1 signaling also downregulates MEG3 to
promote liver fibrosis. A downregulation of MEG3 is achieved by promoter methylation (Yang
et al., 2015).
LncRNA GAS5 inhibits the activation of stellate cells and is another regulator of liver
fibrogenesis. miR-222 targets GAS5 and inhibits its expression, and reciprocally, GAS5 binds
miR-222 to reduce its expression. Both reduction of miR-222 and GAS5 occur at the RNA level.
Therefore, due to competition, higher levels of GAS5 results in greater inhibition of miR-22
expression. As a result of the reduction of miR-222 by GAS5, p27 increases, because miR-222
also binds competitively to inhibit this protein. An increase in p27 results in inhibition of the
activation and proliferation of stellate cells (Yu et al., 2015c).
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Berberine, a compound isolated from Chinese herbal medicines, reduces hepatic steatosis
through lncRNAs to ameliorate Non-Alcoholic Fatty Liver Disease (NAFLD). Steatotic liver
has reduced levels of both lncRNA MRAK052686 and Nrf2, but these levels recover with
berberine treatment. Interestingly, berberine was found to change the expression profiles of 538
lncRNAs in steatotic livers of mice (Yuan et al., 2015).
1.4.3 LncRNAs in Liver Injury
Hematopoietic stem cell transplantation after radiation and chemotherapy can cause
damage to hepatocytes and sinusoidal endothelial cells leading to hepatic veno-occlusive disease,
and lncRNAs have been shown to be affected. LncRNAs were found to be dysregulated in
hepatocytes (2,918 upregulated and 1,911 downregulated) after hematopoietic stem cell
transplantation, and pathway analysis revealed increased T-cell receptor signaling and a decrease
in VEGF signaling (Qiao et al., 2016).
Injury to liver tissue after liver is harvested and placed in cold storage prior to
transplantation is an important concern. TUG1 has been found to be decreased during cold
storage, and overexpression of TUG1 in mouse livers has been found to decrease injury after
cold storage by preventing mitochondrial apoptosis and inhibiting endoplasmic reticulum stress
pathways in hepatocytes and sinusoidal endothelial cells leading to increased graft survival (Su
et al., 2016a).
1.4.4 LncRNAs in HBV and HCV Infection
LncRNAs also have consequences in liver diseases caused by viral infection. Both
hepatitis B virus (HBV) and hepatitis C virus (HCV) have the potential to change cellular
regulatory mechanisms that lead to hepatocellular carcinoma (HCC). HBV and HCV can impact
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chromosomal instability and alter gene expression. HCV, an RNA virus, affects liver and acute
and chronic symptoms resemble HBV symptoms. In contrast to HBV, HCV infection tends to
lead to chronic infection. There is no approved vaccine for HCV, but recently drug treatment has
been shown to cure the disease with a greater than 95% effective rate (Hoofnagle and Sherker,
2014). In HCV related HCC, lncRNA expression profiles are altered including upregulation of
LINC01419 and AK021443, while lncRNA AF070632 is downregulated (Zhang et al., 2015b).
In HBV, hepatitis B virus X protein (HBx) is a well cited transactivating viral protein capable of
dysregulating many liver cell functions including cell cycle progression and apoptosis leading to
HCC. Infection with HBV, a DNA virus, can result in a few weeks of acute symptoms including
vomiting, yellowish skin, tiredness, dark urine, and abdominal pain. Chronic HBV may result in
cirrhosis and liver cancer with death in 15 to 25% of patients. Since 1982, infection by HBV has
been preventable by vaccination (Pungpapong et al., 2007). LncRNA-Dreh may be important in
HBV related liver diseases as it is downregulated by HBx. LncRNA-Dreh was found to be a
tumor suppressor inhibiting tumor growth and metastasis in HCC caused by HBV.
Mechanistically, LncRNA-Dreh was able to repress vimentin by binding the protein which
results in inhibition of tumor metastasis (Huang et al., 2013).
LncRNA HOTAIR and PLK1 kinase are also increased in HBV-induced liver
carcinogenesis. HOTAIR binds both the repressive factors SUZ12 and ZNF198 to enhance
PLK1 ubiquitination and subsequent protesomal degradation of SUZ12 and ZNF198. Their
downregulation leads to epigenetic reprogramming in HBx-expressing cells, notably the
modification of the EPCAM promoter, a gene important for cell adhesion and transformation
(Zhang et al., 2015a).
1.4.5 LncRNAs in Progression of Hepatocellular Carcinoma
13

HCC is the most studied liver disease, and there have been many newly discovered roles
that various lncRNAs play in its progression. HCC is the fifth most common cancer (Parkin et
al., 2005) and the most common liver cancer accounting for 75% of all primary cases (Ahmed
and Lobo, 2009). HCC has many known risk factors, including HBV and HCV (Tanaka et al.,
2011). Treatment includes liver transplantation with a survival rate ranging from 67% to 91%
from studies performed in the late 2000’s (Vitale et al., 2007), pharmacological intervention with
a tyrosine kinase inhibitor, sorafenib, that inhibits tumor-cell proliferation (Llovet et al., 2008),
or surgical resection (Ang et al., 2015).
LncRNA research in liver diseases has focused on HCC and many lncRNAs have been
discovered that are important for disease initiation and progression. Many studies utilize
transcriptome and sequencing analysis to discover lncRNAs that are upregulated or
downregulated at the transcriptome level in HCC compared to normal tissue (Esposti et al.,
2016). Other studies examine variations in lncRNA copy number at the DNA level (Zhou et al.,
2015). From there, the identified differentially expressed lncRNAs are studied further to
determine their exact roles in disease often discovering one or more clear molecular mechanism
for their actions. General characterization studies use tools that indicate regulation pathways
where lncRNAs participate. For example, one particular study finds a total of 5,525 lncRNAs in
23 liver tissue samples comprised of controls, cirrhosis, and HCC and finds 57 differentially
regulated lncRNAs that participate in cell cycle regulation, TGF-β signaling, and liver
metabolism (Esposti et al., 2016). Alternatively, examination of lncRNAs expressed in fetal
liver compared to adult can point to potential oncofetal genes. Often lncRNAs that are
ectopically expressed in adult tissue indicates dysregulation and increased cell proliferation as
seen in cancer or liver regeneration after injury. Many lncRNAs have been discovered to be
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important in liver cancer by this method including lncRNA PVT1 (Wang et al., 2014) and H19
(Ariel et al., 1998).
An example of an HCC liver lncRNA discovered using genome sequencing is lncRNAPRAL. Variations in the copy number of this gene were discovered. Deletion of lncRNA-PRAL,
a lncRNA that induces apoptosis through p53 regulation, has been associated with a decrease in
HCC survival. In mice where tumors have been induced, delivery of lncRNA-PRAL reduces
tumor volume (Zhou et al., 2015). To highlight the various mechanisms lncRNAs can achieve,
we focus here on the molecular mechanisms involved in HCC with emphasis on the similarities
and differences of their molecular functions.
1.4.6 Molecular Mechanisms of LncRNA in Hepatocellular Carcinoma
Recent studies have suggested that initiation of HCC beings with progenitor cells of the
liver rather than the parenchyma. The lncRNA CUDR accelerates liver cancer stem cell growth
by binding cyclin D1 and as a complex, binding both the promoters of H19 and c-myc. Increased
expression of H19 promotes excessive TERT enhancing telomerase activity and c-myc increases
liver cancer stem cell proliferation (Pu et al., 2015). CUDR also interacts with another lncRNA,
HULC, in tumorigenesis (Gui et al., 2015). CUDR enhances embryonic stem cell differentiation
using epigenetic modifying mechanisms. It was shown to inhibit histone H3K27 trimethylation
and to decrease promoter methylation of HULC. CUDR is also capable of changing chromatin
looping promoting recruitment of RNA polymerase II and P300 via CTCF. HULC is also
implicated in promoting angiogenesis by upregulating SPHK1 through sequestering miR-107
which normally targets and inhibits the transcription factor E2F1 (Lu et al., 2016b). LncRNA
DILC represses self-renewal and expansion of liver cancer stem cells and has been found to be
decreased in HCC. DILC binds the IL6 promoter to inhibit its transcription leading to decreased
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STAT3 activation (Wang et al., 2016c). LINC00152 activates the mTOR pathway and binds the
EPCAM promoter to potentially promote cell proliferation (Ji et al., 2015). H19 has been widely
implicated as being important in HCC. H19 knockdown in cancer cell lines, such as Hep3B, has
been shown to decrease tumor weight and tumor volume (Matouk et al., 2007). A microRNA
that is transcribed within the first exon of H19 has been shown to upregulate H19 expression in
HCC. miR675 inhibits HP1α causing histone modifications in the EGR1 promoter (reduced
H3K9 trimethylation, reduced H3K27 trimethylation, and increased H3K27 acetylation)
enhancing its transcription. EGR1 upregulates H19 which activates PKM2 promoting
tumorigenesis (Li et al., 2015a).
Previously mentioned lncRNA PVT1 is increased in HCC and indicates poor prognosis.
PVT1 binding to NOP2 is needed for this lncRNA to increase cell proliferation, cell cycling
genes, and generate a more stem-cell like property of cells. Stabilization and upregulation of
NOP2 is also stabilized by this binding (Wang et al., 2014).
Epigenetic modifying enzymes impart histone modifications or chemically alter DNA
itself, such as simply adding methylation, influence the accessibility of the transcriptional
machinery towards particular genes therefore influencing gene expression. Guide lncRNAs act
by bringing epigenetic modifying enzymes to impact transcription. A clear example of a guide
lncRNA is lncRNA-HEIH. LncRNA-HEIH binds the enhancer EZH2, a component of PRC2,
the histone remodeling complex capable of repressing target genes through methylation of
H3K27 (Yang et al., 2011). LncRNA-HEIH essentially guides the repressive complex to genes
targeted by EZH2. Another example of a guide lncRNA is HOTTIP. However, HOTTIP
interacts instead with a transcriptional activating complex, WDR5/MLL, that promotes HOXA
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genes through H3K trimethylation (Quagliata et al., 2014) showing that liver lncRNAs can act as
both positive and negative regulators of gene expression.
Many liver lncRNAs function as decoys limiting expression of proteins by binding and
sequestering them. For example, lncRNA-Dreh is capable of altering the filament and
cytoskeleton structure of cells by binding vimentin, an intermediate filament protein, to inhibit
its expression (Huang et al., 2013). Similarly, lncRNA-MVIH associates with PGK1, a
glycolytic enzyme, to disallow its function in angiogenesis (Yuan et al., 2012). In converse, the
binding of proteins to lncRNAs can also serve to enhance expression of that protein such as the
scaffold/guide lncRNA-PRAL. LncRNA-PRAL binds HSP90 and p53 promoting HSP90-p53
interaction which stabilizes p53 by disallowing MDM2 binding and ubiquitination of p53 (Zhou
et al., 2015). These mechanisms are also examples of lncRNAs that do not directly bind DNA to
regulate transcription, but rather affect the availability or stability, affecting transcriptional
regulation or simple positive or negative expression of that particular molecule.
LncRNAs can also be destabilized to limit their function as in the case of lncRNA
HULC. IGF2BP1 binds and destabilizes lncRNA HULC through the recruitment of CNOT1
protein, the scaffold of the CCR4-NOT deadenylase complex, which is important for the
cytoplasmic RNA decay machinery (Hammerle et al., 2013). In this example, the lncRNA is not
the decoy, but rather the protein is the decoy titrating away the lncRNA limiting its biological
function to impact gene regulation.
LncRNAs in liver have complex regulation schemes. LncRNA-ATB is regulated by
TGF- ß and then lncRNA-ATB itself regulates multiple signaling processes. Acting as a decoy,
in this case against miRNA instead of protein, lncRNA-ATB titrates away the miR-200 family
(Sun and Wong, 2015). miR-200s act to repress the epithelial-mesenchymal transition (EMT)
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inducing transcription factors, ZEB1 and ZEB2, at the mRNA level. LncRNA-ATB also
regulates the IL-11/STAT3 pathway by stabilizing IL-11 mRNA leading to increased IL-11
protein secretion (Sun and Wong, 2015).
In the previous examples of miRNA regulation, liver lncRNAs require physical binding
to miRNAs serving as decoys titrating away these repressors from being biologically active.
However, lncRNAs can also regulate miRNA by other mechanisms. LncRNA DANCR blocks
miRNA repression by binding CTNNB1 mRNA which is normally repressed by miR-214, miR320, and miR-199a (Yuan et al., 2016). Here, the lncRNA serves not as a decoy but rather a
shield for repression similarly like lncRNA-PRAL that blocks ubiquitination stabilizing p53. In
this example, however, the mRNA and not the protein is protected.
1.4.7 LncRNAs as Biomarkers
Early indication of disease can lead to quicker diagnosis and treatment preceding better
health outcomes due to the prevention of irreversible precipitous disease progression.
Misdiagnosis is also an obstacle in healthcare, because often clinical treatment itself causes death
and disease. For example, globally it has been estimated that 141,700 people died in 2013 from
the effects of medical treatment (Mortality and Causes of Death, 2015) indicating a need for
correct diagnosis preventing unneeded treatments. Finding ways to diagnose that are noninvasive are also more practical, usually more cost-effective, and less harmful to patients.
Therefore, correct, quick, and noninvasive diagnosis is an important health concern, and
biomarkers have become a more widely used useful tool.
Finding new biomarkers indicating disease using body fluids that are easily obtained as
opposed to other methods, such as tissue biopsy, which are invasive and impractical in many
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circumstances, can potentially lead to better and faster diagnosis. Many lncRNAs have been
found in blood that could potentially serve as indicators of disease. For example, APTR is
elevated in serum of patients with liver cirrhosis and research has proposed its role as being
potential marker for the disease (Yu et al., 2015b).
Biomarkers for HCC are also in demand due to the need for early diagnosis of cancer for
better survival potential. Many lncRNAs have been proposed for this purpose. Not only is
MALAT1 expression higher in solid tumors, but elevated levels in the plasma is associated with
liver damage and can predict development of HCC (Konishi et al., 2015). Linc00974 is stably
expressed in plasma, and using qRT-PCR combination analysis for both linc00974 and
CYFRA21-1, an already established tumor marker, high prediction of oncogenesis, tumor
growth, and metastasis in HCC patients could be achieved (Tang et al., 2014). Linc00974
upregulates KRT19 by acting as a competitive endogenous RNA for KRT19’s inhibitor miR642. Increasing KRT19 expression activates Notch and TGF-β signaling.
Other lncRNAs have potential for being serum biomarkers, but have yet been tested for
this purpose. High expression of lnc-DILC predicts early recurrence and short survival of
patients with HCC indicating it may have prognostic value (Wang et al., 2016c), however it has
yet to be tested for its prediction of disease after isolation from blood. Further research that
discovers positive correlation to lncRNAs in blood with early disease need exploration to aid in
early and correct diagnosis for rapid disease treatment.
The contents of extracellular vesicles is gaining new attention emerging as potential
biomarkers for disease. Extracellular vesicles are present in many biological fluids including
blood, urine, and bile (Patel, 2014). To be effective biomarkers, the contents of extracellular
vesicles needs to reflect the contents of the cell of origin, be different between healthy and
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disease, and be reliably detected (Mohankumar and Patel, 2015). Characterization of lncRNAs
differentially expressed in diseased patients from isolated extracellular vesicles has found
promising results. Three potential lncRNA biomarkers, RP11-160H22.5, XLOC_014172, and
LOC149086, were recently found to be upregulated in extracellular vesicles found in plasma of
patients diagnosed with HCC (Tang et al., 2015). And, lincRNA-ROR, which is also packaged
in extracellular vesicles, has the potential to indicate drug sensitivity to chemotherapy against
HCC (Takahashi et al., 2014). Linc-ROR is increased in HCC chemoresistance. With sorafenib
treatment, linc-ROR increases in both cells and extracellular vesicles excreted by tumor cells.
When linc-ROR is increased, there is lower apoptosis and cytotoxicity with drug treatment.
Mechanistically, TGF-β enriches linc-ROR within extracellular vesicles (Takahashi et al., 2014).
1.4.8 Targeting lncRNAs
Novel drug targets to treat disease and biomarkers to correctly and quickly diagnose
disease have the potential to greatly impact human health. New targets will allow for more
effective therapies and reduce the need for drugs with harmful side effects. Due to lncRNAs
being highly tissue specific (Derrien et al., 2012), using them as drug targets has the potential to
reduce off-target effects and limit unwanted, harmful side effects. The liver is an essential organ.
It serves vital functions that are indispensable from the beginning of life before birth to
adulthood. Its necessity is emphasized by its capability to regenerate after injury. Research
discovering the biological functions of lncRNAs is becoming more and more prevalent as their
functions have been found to be more and more abundant and diverse. As more lncRNAs are
discovered to be important in normal growth and in diseased states, more targets for therapies
and biomarkers will be generated. Deeply understanding the mechanisms that lncRNA utilize to
regulate gene function and various other processes will not only give us insights in how our body
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normally functions but also how disease progresses. As technology and innovation advances, the
discovery of new lncRNAs and how they impact the liver will continue and yield fascinating
insights into basic liver physiology and help to better treat liver disease.
1.5. Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver
Diseases
1.5.1 Abstract
H19 is a long non-coding RNA regulated by genomic imprinting through methylation at
the locus between H19 and IGF2. H19 is important in normal liver development, controlling
proliferation and impacting genes involved in an important network controlling fetal
development. H19 also plays a major role in disease progression, particularly in hepatocellular
carcinoma. H19 participates in the epigenetic regulation of many processes impacting diseases,
such as activating the miR-200 pathway by histone acetylation to inhibit the epithelialmesenchymal transition to suppress tumor metastasis. Furthermore, H19’s normal regulation is
disturbed in diseases, such as hepatocellular carcinoma. In this disease, aberrant epigenetic
maintenance results in biallelic expression of IGF2, leading to uncontrolled cellular proliferation.
This section aims to aid further research utilizing H19 for drug discovery and the treatment of
liver diseases by focusing on both the epigenetic regulation of H19 and how H19 regulates
normal liver functions and diseases, particularly by epigenetic mechanisms.
1.5.2 Introduction
H19, a long non-coding RNA (lncRNA), is both epigenetically regulated and utilizes
epigenetic mechanisms to regulate liver cell functions. We will first describe the history of H19
and then focus on the regulation of the gene expression of H19. It is uniquely expressed from
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one allele by an intricate process called genomic imprinting. Then, we will examine H19’s roles
and implications in various normal functions in liver development and growth, including the
regulation of bile acid homeostasis and xenobiotic metabolism. We will discuss dysregulation of
H19 in the progression of liver-related diseases, including steatosis, fibrosis, cirrhosis, diabetes,
and hepatocellular carcinoma (HCC) with a particular focus on the epithelial to mesenchymal
transition (EMT). Finally, we will explore using H19 in therapies for liver diseases either by
targeting H19 or by directly using the H19 promoter to drive selective toxicity in cancer. The
mechanisms of regulation will be highlighted, emphasizing epigenetic mechanisms.
The discovery and characterization of H19, one of the first lncRNAs described,
overviews how lncRNAs were first discovered and assumed to have functions despite not coding
for protein. In 1984, the Tilghman lab discovered an RNA transcript that was highly expressed
in fetal mouse liver, but decreased in adult liver. They screened a fetal liver cDNA library for
moderately abundant clones that hybridized only to a fetal liver cDNA probe, but did not
hybridize to an adult liver cDNA probe and other controls; the clone was designated H19 based
on its position being the 19th clone in row H. In the discussion of their paper, Pachnis et al.
state, “The identity of this protein encoded by H19, if indeed one exists, is unknown at this time”
(Pachnis et al., 1984). Further characterization by sequencing revealed that H19 had multiple
translation termination signals in all three reading frames, but conversely, was highly conserved.
H19 was still transcribed by RNA polymerase II, spliced, and polyadenylated, but puzzlingly did
not associate with ribosomes. This dual nature of being similar to protein-coding genes, but
incapable of translation led the authors to conclude “…the product of this unusual gene may be
an RNA molecule“ (Brannan et al., 1990). Since then, genome-wide technologies, such as
microarrays, particularly tiling arrays, which allow for characterization of sequenced regions
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where function was not known, resulted in a boom of lncRNA discovery. Technology continues
to develop at an alarming rate, and the fascinating H19 discovery was only the beginning of a
new field in science.
There are numerous reviews discussing the vast amount of research on H19. Prior
reviews cover topics as extensive as H19’s regulation (Sasaki et al., 2000; Banerjee et al., 2001;
Gabory et al., 2006; Nordin et al., 2014), or its broad role in cancer (Raveh et al., 2015; Jing et
al., 2016; Matouk et al., 2016). Other reviews are more specific to particular types of cancer
(Wake et al., 1998; Matouk et al., 2015; Lin et al., 2016). There is a need for more reviews
discussing diseases in a particular organ, especially the liver. When H19 is discussed in the
context of HCC, reviews examine other lncRNAs in their analysis without focus on H19. First,
will be a description of H19’s role in liver diseases, including HCC, with a particular emphasis in
any epigenetic regulation where H19 participates. We will also highlight research from other
organ systems that need translational examination in the liver. Overall, we aim to provide a
resource for future research on H19, so liver diseases may be treated more effectively in the
future.
1.5.3 Characterization of H19 and Its Participation in Epigenetic Regulation
1.5.3.1. LncRNAs
LncRNAs are transcripts greater than 200 nucleotides that do not code for proteins.
Despite not being translated, approximately 35,000 lncRNAs have been discovered that exhibit
characteristics of mRNA, such as being 5′ capped, spliced, and poly-adenylated (Carninci et al.,
2005). Furthermore, lncRNAs are generated similarly to proteins, having similar histonemodification profiles, splicing signals, and exon and intron lengths (Derrien et al., 2012).
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LncRNAs are abundant, comprising 80% of all transcripts (Kapranov et al., 2007) and their
expression levels are highly tissue specific (Derrien et al., 2012).
Molecular functions of lncRNAs are described as signals, decoys, guides, and scaffolds
(Wang and Chang, 2011). LncRNAs act effectively as signals due to their specific expression in
specific cell types and stages of development as well as their capability to respond to stimuli.
Many lncRNAs found in liver currently described in the literature can be classified as signals due
to being tissue specific, disease state specific, and/or developmentally specifically expressed.
LncRNAs also act as decoys by binding and titrating away proteins. They can be guides capable
of binding regulatory molecules, including chromatin remodelers and transcription factors,
directing them to specific DNA targets to control gene expression. With different domains
capable of binding different molecules, they can also be scaffolds, assembling a complex
arrangement of components (Wang and Chang, 2011). Thus, lncRNAs can exhibit many
functions and work within the cell to regulate different processes by various molecular
mechanisms.
1.5.3.2 H19
The characteristics of H19 are similar to other lncRNAs in both structure and their
temporal and tissue-specific expression pattern. Structurally, the H19 gene contains five exons
and four introns, producing a 2.3-kb lncRNA after splicing. The H19 gene contains shorter
introns than most lncRNA genes, each less than 100 base pairs (Kent et al., 2002). It is
transcribed from chromosome 7 in the mouse and chromosome 11 in the human. It is adjacent to
the protein-coding gene, insulin-like growth factor 2 (IGF2), an important fetal growth factor.
These two genes share regulatory sequences required for their expression, including two
enhancers located 3’ downstream of H19 (Leighton et al., 1995b). Their expression is also
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controlled by an imprinting control region (ICR) between the two gene loci and exhibits
differential methylation (Drewell et al., 2002). Temporally, H19 is expressed in the embryo, but
subsequently downregulated in all tissues, excluding skeletal muscle, shortly after birth
(Brunkow and Tilghman, 1991). During the fetal and postnatal ages, H19 is abundant in the
liver. H19 expression has been shown to correlate with the expression of IGF2, implicating
H19’s important role in liver development.
H19 has many diverse biological functions. It is known to participate in the regulation of
cell proliferation (Yamamoto et al., 2004) and differentiation (Dey et al., 2014), as well as its
role in cancer both as an oncogene (Hibi et al., 1996; Barsyte-Lovejoy et al., 2006) and as a
tumor suppressor (Yoshimizu et al., 2008). In the developing fetus, H19 regulates a number of
important genes within the imprinted gene network (IGN), including Igf2, responsible for proper
embryonic development (Gabory et al., 2010). Due to participating in many known biological
functions and being one of the first lncRNAs discovered and characterized, H19 is one of the
most well-studied lncRNAs.
The H19 locus harbors multiple transcripts (Figure 1.1). The main transcript, H19,
functions as the full lncRNA, and it encodes within its first exon two variants of microRNA,
miR-675 (Dey et al., 2014). There are also two antisense transcripts produced from the locus,
91H and HOTS. The HOTS transcript can produce a nucleolar protein (Onyango and Feinberg,
2011), while 91H appears to function solely as an lncRNA (Berteaux et al., 2008). A review and
discussion on the antisense transcripts is presented in Section 1.5.7.
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Figure 1.1 Transcription at the H19 locus consists of the well-characterized H19 lncRNA (A)
and its microRNA miR-675 (B) encoded within the first exon of H19. Two antisense transcripts
are also formed from the locus. 91H RNA (C) is described as varying in length, but can
potentially be transcribed from the complementary DNA strand entirely encompassing H19 and
other portions of its regulatory sequences. HOTS RNA (D) is transcribed from most of the
antisense sequence of H19 and upstream bases. HOTS can be translated to form a nucleolar
protein.
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1.5.3.3 Regulation of H19 Expression by Epigenetic Mechanisms
H19 is regulated by the epigenetic phenomenon, genomic imprinting. Normally, H19 is
only expressed from one parental allele and silenced epigenetically on the reciprocal
chromosome. The paternal allele is imprinted, or silenced, due to the highly methylated ICR
found between H19 and IGF2. The ICR is a differentially methylated region (DMR) due to
having different methylation statuses depending on the chromosomal parental origin. At the
maternal allele, H19 is expressed, and on this chromosome, the ICR is hypomethylated
(Manoharan et al., 2004). IGF2 is also imprinted, but opposite of H19, expression is driven from
the paternal allele and the maternal allele is silenced (DeChiara et al., 1991). The same ICR also
controls IGF2 imprinting. Located approximately 2 kb upstream of the H19 promoter between
H19 and IGF2, this region regulates monoallelic expression of those genes by being
differentially methylated depending on the parental origin of the allele. In normal conditions, the
ICR is hypermethylated at the paternal allele and hypomethylated at the maternal allele. This
balance is important in controlling normal expression of these genes. Deleting 10 kb upstream
H19 disrupts this region and causes biallelic IGF2 expression, thereby disrupting imprinting
(Ripoche et al., 1997). The mechanism controlling imprinting of H19 and IGF2 involves the
binding of either MeCP2 or CTCF based on the methylation status of the ICR.
On the hypermethylated ICR found on the paternal chromosome, H19 is repressed and
IGF2 expressed. H19 expression is silenced through histone deacetylation by MeCP2 binding to
methylated CpG dinucleotides. After binding, histone deacetylases (HDACs) interact with
MeCP2 to repress H19 (Drewell et al., 2002). Furthermore, in this state of ICR methylation, the
ICR binds another DMR located within IGF2, DMR2. This ICR and DMR2 interaction moves
IGF2 into position to interact with the enhancer region driving IGF2 expression (Kurukuti et al.,
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2006). The binding of the insulator CTCF to the ICR is disallowed due to the high number of
methyl groups (Kurukuti et al., 2006).
Conversely, on the hypomethylated ICR found on the maternal chromosome, H19
expression is not repressed by MeCP2 binding and able to interact with its enhancer region.
CTCF is allowed to bind, insulating and preventing the expression of IGF2 by two known
mechanisms. First, CTCF binding allows the interaction of the ICR with matrix attachment
region 3 (MAR3) and another DMR, DMR1, which is located in an intergenic region of IGF2.
These interactions result in a loop around IGF2 and impediment of expression (Kurukuti et al.,
2006), as well as disallowing the enhancers from interacting with IGF2 (Murrell et al., 2004).
Specifically in liver, the binding of CTCF to the ICR is mediated by the interaction of CTCF
with prohibitin 1 (Ramani et al., 2016). Second, CTCF interacts with the IGF2 promoter region
and recruits polycomb repressive complexes leading to H3K27 methylation causing suppression
of IGF2 (Li et al., 2008).
In summary, two states on separate parental alleles exist in normal conditions when H19
and IGF2 are co-expressed. On the paternal allele, the ICR is methylated, and the enhancer
region is able to interact with IGF2 to allow expression. On the maternal allele, the ICR is not
methylated, allowing the same enhancer region to, instead, drive H19 expression. Therefore, this
region and its methylation status are critical for both H19 and IGF2 expression, expressed
coordinately albeit from opposite alleles.
1.5.3.4 H19 Regulates Gene Expression by Epigenetic Mechanisms
Activating or repressing H19 may be important as an epigenetic therapy for future
treatment of epigenetic abnormalities in diseases. In this section, we aim to highlight known
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cases where H19 directly participates in either the repression or activation of transcription
through direct epigenetic mechanisms. First, we will examine H19 in the repression of genes
and, second, in the activation of genes. Finally, we will examine how H19’s role as an
epigenetic modifier impacts chemotherapy resistance. In these examples, H19 plays a clear role
in affecting transcription through chromatin remodeling.
In many examples, H19 recruits epigenetic modifiers, acting as a guide to repress gene
expression. Important for embryonic development, H19 controls at least nine imprinted genes
(Igf2, Igf1r, Dlk1, Meg3, Slc38a4, Peg1, Dcn, Cdkn1c, and Gnas) in the mouse IGN (Monnier et
al., 2013). The control over some of these genes occurs by H19 interaction with methyl-CpGbinding domain protein 1 (MBD1), a protein in the same family as MeCP2 (discussed earlier as a
repressor of H19 expression). MBD1 binds to methylated DNA to recruit HDACs and histone
lysine methyltransferase (KMT)-containing complexes, SETDB1 and SUV39H1, silencing genes
via H3K9 methylation, inducing chromatin compaction (Figure 1.2 A) (Monnier et al., 2013). In
a second example, H19 represses gene expression through the interaction with enhancer of zeste
homolog 2 (EZH2), a H3K27 methyltransferase in a part of the polycomb repressive complex 2
(PRC2) in bladder cancer. H19 association with EZH2 results in the activation in Wnt signaling
and recruitment of PRC2 to silence E-cadherin (Figure 1.2 B) (Luo et al., 2013). Although, the
direct H19 and EZH2 binding has not been determined in liver, EZH2 has been shown to silence
tumor suppressor microRNAs in liver cancer and is upregulated in HCC (Au et al., 2012). It
would be interesting to examine H19’s role in HCC to determine if they are binding partners in
this condition.
H19 can also promote gene expression by acting as a guide for epigenetic modifying
enzymes. For example, H19 binds hnRNP U, part of a complex with RNA polymerase II and a
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histone acetyltransferase, PCAF. Histone acetylation results in the upregulation of genes within
the miR-200 family. Activation of the miR-200 family ultimately suppresses metastasis in HCC
(Figure 1.3) (Zhang et al., 2013). These examples highlight how H19 can both repress and
activate gene expression by epigenetic mechanisms, making context crucial in understanding its
functions.
H19’s role as an epigenetic modifier may also be important in the study of a barrier in
cancer treatment, chemotherapy drug resistance. P-glycoprotein, an efflux transporter, is often
upregulated in cancer cells. This prevents cancer drugs from accumulating in cancer cells,
thereby reducing their efficacy. H19 may induce P-glycoprotein expression by regulating MDR1
promoter methylation (Tsang and Kwok, 2007). In a doxorubicin-resistant hepatocellular
carcinoma cell line, R-HepG2, it was found that knockdown of H19 resulted in an increase of
promoter methylation at the MDR1 promoter. Establishment of the mechanism, by which H19
regulates the promoter methylation status of efflux transporters in chemotherapy drug resistance,
will further define H19’s role to influence gene expression as an epigenetic modifier.

31

32

Figure 1.2. Epigenetic regulation by H19. H19 acts to repress genes within the imprinted gene
network, such as IGF2. H19 binds MBD1. MBD1 then binds methylated DNA and then recruits
histone lysine methyltransferases (KMTs) to silence these genes by chromatin compaction (A).
H19 silences E-cadherin. H19 binds EZH2, a H3K27 methyltransferase part of the PRC2,
causing downregulation of E-cadherin (B).
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Figure 1.3. H19 can also activate gene transcription. H19 binds hnRNP U, which is a member
of the complex with RNA Polymerase II and PCAF, a histone acetyltransferase. H19 binding
results in the upregulation of the miR-200 family of microRNAs through histone H3 acetylation.
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1.5.4 The Roles of H19 in Normal Liver Functions
1.5.4.1 The Roles of H19 in Liver Development
The liver is an essential organ for life. Hepatocytes, the main parenchyma of the liver,
comprise almost 80% of the adult liver’s total mass (Kmiec, 2001). The remaining mass
includes cholangiocytes, sinusoidal endothelial cells, stromal cells, Kupffer cells, and stellate
cells. The liver has many important biological functions, such as detoxification, modification
and excretion of exogenous and endogenous substances, the synthesis of cholesterol, bile salts,
and phospholipids, and blood glucose regulation (VanPutte et al., 2013). The liver is also the
major organ for hematopoiesis in the fetus (Georgiades et al., 2002). We will examine H19’s
role in some of these major processes, including its role when these processes are not functioning
normally in disease.
Many studies have shown that lncRNAs are important regulators of normal liver
development. LncRNAs are differentially expressed throughout different stages of development
from embryogenesis to adult life. Our lab has previously characterized, using whole
transcriptome analysis, the expression patterns of liver lncRNAs by RNA-sequencing in mice
before birth to adult (Peng et al., 2014). We have discovered that there are three major oncogenic
patterns of differential expression and potentially a functional transition of lncRNAs that occur at
the neonatal, adolescent, and adult stages, implying their importance in liver maturation. H19
was found to be the most differentially expressed annotated lncRNA between fetal and adult
liver. Mechanistically, H19 expression is drastically silenced at the postnatal age due to
transcriptional repression by zinc fingers and homeoboxes 2 (Zhx2) protein (Perincheri et al.,
2005), the same protein that regulates alpha-fetoprotein, which led to H19’s initial discovery
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(Pachnis et al., 1984). This intricate temporal control indicates H19 is a regulator of liver
development.
H19 controls liver growth and potentially the decline of the hematopoietic role of the
liver after birth through the IGN. The decline of the expression of genes within the IGN
coordinates the deceleration of organ growth, including the liver after birth (Lui et al., 2008). As
previously described, H19 has been shown to regulate genes within the IGN by epigenetic
mechanisms (Monnier et al., 2013), indicating that H19 has a major influence on development.
Igf2 and Dlk1, both in the IGN, are also important for hematopoiesis (Zhang and Lodish, 2004;
Sakajiri et al., 2005), and the liver is the main site of hematopoiesis during birth. The repression
of Igf2 and Dlk1 by H19, which has been shown experimentally, indicates that H19 is potentially
responsible for the developmental switch of the liver starting as a hematopoietic organ to an
organ that focuses mainly in metabolism. H19’s control over the IGN leads to many
implications on its role in regulating liver development.
H19 also regulates the proliferation of liver in development by Wnt signaling. The Wnt
signaling pathway is critical for postnatal liver growth (Apte et al., 2007). H19 inhibits
proliferation in fetal liver by inhibiting the canonical Wnt signaling pathway through inhibition
of its major intracellular signal transducer, β-catenin (Wang et al., 2016b). H19 can block the
interaction of hnRNP U with actin, leading to transcriptional repression of genes involved in the
Wnt signaling pathway (Wang et al., 2016b). Despite these two mechanisms, there is also
evidence of H19 activating Wnt signaling, albeit in a different context and cell type: bladder
cancer (Luo et al., 2013). These examples show how H19 can act by different mechanisms to
affect one master regulation pathway. In the context of liver proliferation in development, H19
appears to be a negative regulator of Wnt signaling.
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The microRNA encoded within H19, miR-675, is also potentially important for
development. The RNA binding protein, HuR, blocks the processing of miR-675 from H19, but
during gestation, HuR is downregulated, causing miR-675 expression. Overexpression of miR675 in extraembryonic cell lines causes reduced proliferation. Mechanistically, miR-675 inhibits
Igf1r, and this inhibition can limit placental growth (Keniry et al., 2012).
H19 is also implicated in abnormal fetal development, regulated by epigenetic
mechanisms. Developmental-specific methylation occurs at different regions around the
H19/IGF2 locus in DMRs in promoters for both genes (Li et al., 1998). DNA methylation of
imprinted genes is first erased in primordial germ cells and reestablished later in the formation of
gametes (Arnaud, 2010). In vitro fertilization (IVF) may disrupt normal embryonic and fetal
growth, causing abnormal gene expression in liver. Through disruption of epigenetic regulatory
networks, errors on both the maternal and paternal alleles occur at the H19 DMR and the IGF2
DMR2, respectively. H19 is significantly downregulated, and IGF2 is upregulated in livers of
mice at birth and three weeks of age if they were conceived via IVF. At 1.5 years of age, mice
conceived via IVF had significantly lower H19 and IGF2 expression in liver. IVF causes
hypomethylation at the H19 DMR, indicating that early life manipulation affects vulnerability to
differential methylation. In humans, growth disorders are higher and birth weights are lower in
newborns conceived by IVF (Le et al., 2013). This study highlights the importance of
maintaining proper methylation statuses at the H19/IGF2 locus in development.
1.5.4.2 The Roles of H19 in the Regulation of Xenobiotic Metabolism and Transport
The liver is the most important organ for metabolizing endogenous compounds and
xenobiotics, including drugs. The liver contains multiple classes and families of metabolizing
enzymes. These enzymes participate in reactions to make xenobiotic compounds more water
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soluble and capable of clearance through excretion in the urine or transportation into the bile.
For example, the cytochrome P450 enzymes are a class of phase I enzymes. They typically
function as monooxygenases that insert oxygen into molecules, making them more water soluble
and easier to clear from the body (Werck-Reichhart and Feyereisen, 2000).
Phase II enzymes are drug-metabolizing enzymes capable of conjugation reactions (Jancova et
al., 2010). Drug transporters are also important for clearing xenobiotics from the body
(Klaassen, 2002). Efflux transporters, such as MDR1, are upregulated in HCC (Bonin et al.,
2002), often inhibiting chemotherapy drugs from effectively inhibiting cancer cells. Currently,
there is little research on how lncRNAs affect xenobiotic metabolizing enzymes, particularly in
mammalian systems, indicating a knowledge gap and a potential area for further study.
H19 affects drug transporter and phase II conjugation, resulting in alteration of the
metabolism and disposition of drugs. H19 is overexpressed in a number of drug-resistant cell
lines, including doxorubicin-resistant liver cancer cells (Tsang and Kwok, 2007) and cisplatinresistant ovarian cancer A2780-DR cells (Zheng et al., 2016). In both studies, knockdown of H19
expression results in restored chemotherapeutic sensitivity. The doxorubicin-resistant liver
cancer cells exhibit an overexpression of the transporter MDR1. Sensitivity is restored by
methylation of the MDR1 promoter, causing its repression and inability to efflux the drug (Tsang
and Kwok, 2007). In the cisplatin-resistant ovarian cancer cells, H19 knockdown coincided with
a reduction of glutathione S-transferase P1 (GSTP1), responsible for cisplatin inactivation
(Zheng et al., 2016). Examination of changes in phase II glutathione conjugation and in drug
transporters after H19 knockdown in liver cancer cell lines should further be explored, as these
enzymes are important for clearing drugs and for the accumulation of drugs in cancer cells.
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Although H19 has not been directly linked to the regulation of phase I metabolism
enzymes, current research may support H19 having a role. Gene expression profiles of P450
enzymes change in the developing liver, and normal adult P450 expression is not established in
mice until a specific postnatal age (Hart et al., 2009). This change corresponds inversely with
the expression pattern of H19 in liver. ZHX2, described earlier as the repressor that targets H19
for silencing in postnatal liver, also regulates sexually dimorphic, developmentally-regulated
P450 genes in liver, including Cyp2a4, Cyp2b13, and Cyp4a12 (Townsend Creasy et al., 2016).
Human CYP2A6 has the highest homology to mouse Cyp2a4, and CYP2A6 is responsible for
metabolizing nicotine, carcinogens, and several pharmaceuticals. Although there is no direct
link of H19’s role in regulating these enzymes, its direct repressor has been described as
important. Further research is needed to determine if H19 regulates phase I metabolism and its
implication on the metabolism of drugs, especially in the fetus and in postnatal liver. This
research will aid our understanding of how the fetus, neonates, and children handle drugs while
they express H19 compared to adults without H19 expression in liver.
1.5.5 The Roles of H19 in the Progression of Liver Diseases
1.5.5.1 The Roles of H19 in the Development of Steatosis, Fibrosis, and Cirrhosis
Targeting H19 in cholestatic liver fibrosis may reduce liver injury. Accumulation of bile
acid leads to cell injury, causing inflammation and fibrosis (Zollner and Trauner, 2009). One
cause of cholestasis is the buildup of cytotoxic bile acids due to bile acid synthesis and
accumulation from blocked uptake into hepatocytes and inhibited renal excretion via NTCP
(Zhang et al., 2016). Although H19 does not seem to play a role in bile acid synthesis, its direct
repressor, SHP, represses CYP7A1 and CYP8B1 after activation by FXR. The antiapoptotic
protein, BCL2, appears to have an overarching control over SHP and H19. Mechanistically,
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BCL2 overexpression results in a drastic 47-fold increase in H19 due to its degradation of the
SHP repressor. The molecular basis, by which H19 regulates liver fibrosis, has yet to be
completely determined. Despite not directly controlling P450s or FXR expression, the
knockdown of H19 still partially rescues BCL2-induced liver injury (Zhang et al., 2016). This
partial rescue of injury may be an important observation for the treatment of cholestatic liver
fibrosis pointing to H19 as a target for potential therapy.
Another condition, non-alcoholic fatty liver disease (NAFLD), occurs when fat is
deposited in liver, steatosis. LncRNAs, including H19 and its co-regulated protein-coding
partner, IGF2, may play important roles in this disease progression. One study found that
approximately 500 lncRNAs were upregulated and 1,200 lncRNAs were downregulated in
human livers of patients with NAFLD compared to healthy livers (Sun et al., 2015). Another
study links H19 to steatosis through PLIN2, a member of the lipid droplet protein family that is
markedly increased in fatty liver. When PLIN2 was inhibited, a 548-fold increase in H19 was
observed with a significant decrease in liver triglycerides (Imai et al., 2012). In another study,
p62, a binding protein of IGF2 mRNA, was highly expressed in diseased liver. When
overexpressed in mice, p62 can induce the steatotic phenotype (Tybl et al., 2011), including a
two-fold increase in triglycerides compared to wild type (Laggai et al., 2013). It was first found
that p62 expression did not induce inflammation, showing correlation to NAFLD, but not
progressing fully to NASH. However, other researchers have reported p62 overexpression
resulting in the activation of NF-κB, suggesting an increased inflammatory response and
progression to NASH (Simon et al., 2014).
NAFLD can progress to its most extreme form, non-alcoholic steatohepatitis (NASH).
NASH is the major cause of cirrhosis of the liver. Cirrhosis, a disease where the liver does not
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function properly due to long-term damage, resulted in 1.2 million deaths in 2013 (Mortality and
Causes of Death, 2015). Cirrhosis is usually caused by alcohol or hepatitis B or C. Fibrosis, or
scarring of the liver, and steatosis, fatty liver, often precedes cirrhosis. Hepatic stellate cells are
the main extracellular matrix producing cells and upon activation can promote fibrosis and
cirrhosis. H19 is known to sequester miR-874 in the intestinal barrier (Su et al., 2016b), and this
microRNA is upregulated in hepatic stellate cells upon activation, potentially implicating a
mechanism that needs further study (Kitano and Bloomston, 2016). Furthermore, whole
transcriptome RNA-sequencing analysis was performed in cirrhotic livers compared to normal
healthy tissue, and H19 was discovered to be upregulated in cirrhotic liver tissue (Esposti et al.,
2016). Only correlation of H19 to this disease has been reported, and these studies do not
examine mechanism, again indicating a need for further research. It is clear, however, that
lncRNAs, including H19, are involved in NAFLD and potentially to its progression to NASH.
1.5.5.2 The Roles of H19 in the Regulation of Diabetes
The body needs to maintain blood sugar at precise levels and the liver is a major site of
glucose regulation. In times of low blood sugar, the alpha cells of the pancreas secrete glucagon,
stimulating the liver to release glucose stores and induce the production of more glucose through
gluconeogenesis. Conversely, glycogenesis, the process of generating glycogen from glucose, is
stimulated by insulin generated in the beta cells of the pancreas when blood glucose levels are
high. Insulin promotes the liver and muscle to take up blood glucose, effectively dropping blood
glucose levels. Diabetes mellitus (DM) is a disease caused by prolonged increased blood sugar
levels due to dysregulation of these processes. DM is caused by either the pancreas not
producing enough insulin (type I DM) or the body, including the liver, not properly responding
to insulin (type II DM) (Roder et al., 2016).
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There is superficial evidence for H19's significance in type II DM. Smooth muscle cells
cultured in the presence of insulin express a five-fold increase in H19 than when cultured in
media alone (Han et al., 1996). This indicates that H19, at the very least, responds to changes in
insulin. Mice with a whole-body knockout of H19 expression (through targeted deletion at the
maternal allele) are 27% heavier (Leighton et al., 1995a) due to this mutation, which also results
in biallelic expression of IGF2 (Ripoche et al., 1997) and improper growth after birth,
predisposing them to type II DM (Eriksson et al., 2003). These observations begin the story, but
more convincing mechanistic studies examining changes in the epigenetics profiles of H19 and
IGF2 are needed to fully determine H19’s role.
Epigenetic phenomenon in the liver at the ICR between H19 and IGF2, and H19
expression are proposed to play a role in type II DM. In a study examining differential mRNA
expression levels and patterns of DNA methylation in liver tissue, significant differences were
observed between normal patients and patients with type II DM, such as an increase in H19
expression and the degree of methylation at its gene locus (Nilsson et al., 2015). Another study
reported a significant degree of hypomethylation at the H19 locus in an insulin-resistant female
(Murphy et al., 2012). Currently, there is little research on the mechanism of insulin resistance
in the liver regarding H19; only associations regarding expression and methylation status have
been characterized. Because the liver is a major site of insulin resistance in type II DM, there is
the need for further research in liver, specifically. There is also significant evidence that H19 is
important in other tissues, such as insulin resistance in muscle and insulin production in the
pancreas due to glucose intolerance.
H19 plays a role in both humans and mice with type II DM in the muscle. H19 was
shown to be significantly decreased and to act as a decoy for microRNA let-7 (Gao et al., 2014).
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H19 acts as a sponge that sequesters let-7, which targets genes, such as Insr and Lpl, to inhibit
the insulin-PI3K-mTOR pathway. Downregulation of H19 in diabetic muscle limits let-7
sequestration, subsequently increasing inhibition of the pathway and promoting insulin
resistance. Let-7 has also been reported to destabilize and downregulate H19 as a protective
mechanism in hyperinsulinemic conditions in non-diabetic muscle cells via a KSRP-dependent,
insulin/PI3K/AKT signaling system. Chronic downregulation of H19 limits glycogenesis and
interferes with normal glucose metabolism (Gao et al., 2014). Examining how H19 interacts
with let-7 in liver may yield parallel mechanisms. Let-7 is expressed in liver, and as stated
earlier, H19 expression was shown to increase in patients with type II DM. Another example of
H19 sequestering microRNAs affecting important signaling pathways important for glucose
regulation was studied in tendon-derived stem cells. Here, H19 directly targets miR-29b-3p (Lu
et al., 2016a). This microRNA has also been shown to lead to dysregulation of insulin/PI3KAKT signaling in both the livers and pancreases in a mouse model that develops hyperglycemia
(Kwon et al., 2014). Translational research is needed to further elucidate H19’s role on these
targets in liver.
The pancreas is another site of differential methylation of the H19 ICR in mice exposed
to high intrauterine glucose, resulting in diabetes. Researchers induced diabetes in pregnant
females. As a result, their pups received a high exposure to glucose, leading to low expression
levels of H19 and IGF2. Low expression was due to hypermethylation of the ICR in the pups'
pancreatic islets. Low expression of H19 and IGF2 was also observed in the sperm of these
mice. This indicates high intrauterine glucose exposure can cause glucose intolerance, and this
disease state can be passed down further to future offspring (Ding et al., 2012). This study
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provides a compelling mechanism for the inheritance of childhood diabetes with H19 as a
significant factor.
H19 may act differently in different tissues impacting diabetes in a multifaceted fashion.
Diabetes linked to H19 in liver has been severely understudied, despite being an important organ
in insulin resistance. H19 has been shown to regulate glucose intolerance and insulin resistance,
but studies have mainly focused on muscle and the pancreas. Discovering how H19 participates
in this disorder in the liver will allow for a more systemic understanding of the problem.
1.5.5.3 The Roles of H19 in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a serious disease with few treatment options, needing
more targeted therapies for better treatment. HCC is the fifth most common cancer (Parkin et al.,
2005) and the most common liver cancer, accounting for 75% of all primary cases (Ahmed and
Lobo, 2009). HCC has many known risk factors, including hepatitis B and C (Tanaka et al.,
2011). Treatment includes liver transplantation with a survival rate ranging from 67% to 91%
from studies performed in the late 2000s (Vitale et al., 2007), pharmacological intervention with
a tyrosine kinase inhibitor, sorafenib, for inhibiting tumor-cell proliferation (Llovet et al., 2008)
or surgical resection (Ang et al., 2015). HCC is the most studied liver disease, and there have
been many newly-discovered roles that various lncRNAs play in its progression, paving the way
for new drug targets.
H19’s importance has been widely implicated in HCC; however, reports are inconsistent
in its role of promoting cancer as an oncogene or acting as a tumor suppressor. Raveh et al.
recently published an excellent extensive review regarding H19’s role in cancer initiation,
progression, and metastasis, where they aimed to resolve conflicting literature (Raveh et al.,
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2015). There are many differences in HCC compared to other cancers, so the need to
concentrate attention on mechanisms specific to liver is important. For instance, there is a
difference in how p53, the tumor suppressor regarded as guardian of the genome, behaves in
different cancers. It appears p53 does not control the reemergence of H19 expression in HCC as
it functions in other cell types. In HeLa cells derived from cervical cancer, repression of H19 by
p53 was observed at the H19 promoter (Dugimont et al., 1998). In the thymus, p53 also
suppresses H19 by regulating DNA methyltransferase expression profiles. This causes
methylation at the H19 ICR, leading to changes in H19 and IGF2 expression (Park et al., 2005).
In the liver, however, p53 does not contribute to the methylation status of the ICR, and
insignificant changes in H19 and IGF2 expression were observed after knockout of p53 (Park et
al., 2005). This example highlights how H19 is regulated differently between different cancers
and cell types, as well as the need to focus on H19 in the context of HCC.
Many examples discuss H19 promoting cancer. The reemergence of H19 and IGF2
expression in HCC alone implicates them as positive regulators. After H19 and IGF2 are
downregulated at the postnatal ages, they are both reactivated to be expressed in adult livers with
HCC (Cariani et al., 1988; Ariel et al., 1997; Kim and Lee, 1997). Both genes exhibit biallelic
expression due to a dysregulation of their imprinting (Kim and Lee, 1997). H19 re-expression
might be explained by repression of Zhx2, the gene that silences H19 at the postnatal age, in
HCC, through promoter methylation (Lv et al., 2006). Targeting H19 expression may be a
potential therapy, as H19 knockdown in cancer cell lines, such as Hep3B, has been shown to
decrease tumor weight and tumor volume (Matouk et al., 2007).
HCC tumorigenesis promotion is also regulated by miR-675 through various
mechanisms. First, miR-675 directly increases proliferation in HCC by affecting cell cycle
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regulation through the inhibition of retinoblastoma protein (Hernandez et al., 2013). Second,
miR-675 upregulates H19 expression. Molecularly, miR-675 inhibits HP1α causing histone
modifications (reduced H3K9 trimethylation, reduced H3K27 trimethylation and increased
H3K27 acetylation) at the EGR1 promoter, enhancing its transcription. EGR1, in turn,
upregulates H19, activating PKM2. Ultimately, this results in tumor formation and the
promotion of angiogenesis (Li et al., 2015a).
Tumors transitioning from benign to malignant undergo angiogenesis, and H19 impacts
this area of tumorigenesis, as well. To stimulate angiogenesis, H19 has been found to be
released from the exosomes of CD90+ liver cells to endothelial cells. H19 then induces the
expression of various transcripts, such as VEGF, known to stimulate angiogenesis in endothelial
cells (Conigliaro et al., 2015). Angiogenesis inhibitors are used in the treatment of cancer
pointing to H19 as a potential target in this example. Previously mentioned sorafenib displays
antiangiogenic activity outside of its main mechanism to suppress tumor growth (Gotink and
Verheul, 2010). Suppressing H19 may also help to treat HCC through inhibition of
angiogenesis.
Other lncRNAs regulate liver cancer in tandem with H19. Recent studies have suggested
that initiation of HCC can start with progenitor cells of the liver rather than the parenchyma. The
lncRNA CUDR accelerates liver cancer stem cell growth by binding cyclin D1 and, as a
complex, binding both the promoters of H19 and c-Myc. Increased expression of H19 promotes
excessive TERT enhancing telomerase activity, and c-Myc increases liver cancer stem cell
proliferation (Pu et al., 2015). These well-defined mechanisms support the role of H19 being an
oncogene. However, H19 can also assume a role in contrary to the promotion of HCC. There is
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increasing evidence that supports H19 as being a tumor suppressor acting to inhibit metastasis
(Hernandez et al., 2013; Zhang et al., 2013).
1.5.5.4 The Roles of H19 in the Epithelial-to-Mesenchymal Transition
Tumor metastasis requires the ability of cancer cells from a primary site to invade a
secondary site. In order for this to occur, the cancer must transition from its originating cell type
to a cell type capable of differentiating into various other cell types. EMT occurs when epithelial
cells become mesenchymal cells with this capability. An original cell loses its polarity and cellto-cell adhesion, gaining migratory and invasive properties. This gives the cell the ability to
differentiate back into a cell type of the tissue it has invaded.
Epigenetic changes are involved in cancer metastasis in HCC, and H19 has been shown
to impact pathways, resulting in epigenetic changes leading to tumor suppression. The next
example was previously discussed in a prior section examining H19 regulation by epigenetic
mechanisms. H19 suppresses metastasis by repressing markers for EMT through the regulation
of the miR-200 family. The markers for EMT examined (E-cadherin, cytokeratin-8, cytokeratin19, and claudin 1) were increased following H19 knockdown, indicating H19 inhibits EMT.
H19 accomplishes this via histone acetylation to activate the miR-200 pathway after complexing
with hnRNP U/PCAF/RNA Pol II (Zhang et al., 2013). The miR-200 family was found to
enhance E-cadherin expression in two different HCC cell lines (Hung et al., 2013). The miR-200
family achieved this enhancement by directly targeting E-cadherin’s transcriptional repressors,
ZEB1 and ZEB2, as determined in NMuMG murine mammary epithelial cells (Korpal et al.,
2008). E-cadherin expression enhancement hinders EMT in an in vitro model of EMT induced
by transforming growth factor-β in NmuMG cells. E-cadherin expression also decreases motility
in different cell lines derived from cancer, including HepJ5 cells, an HCC cell line (Hung et al.,
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2013). Again, the H19 transcript is not fully responsible for its function in EMT, as miR-675
also plays a role. Evasiveness is reduced by inhibiting Twist1, a key mediator of EMT
(Hernandez et al., 2013). Despite the previous assumption that H19 promotes HCC by
increasing proliferation and angiogenesis, H19 opposes metastasis. Understanding this
complicated interplay between H19 acting as an oncogene and a tumor suppressor results in a
more complex, but clearer picture of how H19 participates in each role.
1.5.6 Targeting H19 for Development of Therapeutic Approaches for Liver Diseases
New therapies to treat liver diseases are needed and more research will need to follow
before effectively utilizing H19. Currently, there is very little research connecting H19 to
diseases, such as type II DM or NAFLD and NASH, and more studies are needed before
therapies can be designed utilizing H19 as a target. However, there is exciting research using
H19 to treat HCC, which is greatly needed. Currently, there is only one approved
pharmacological intervention to treat HCC, sorafenib. In 2008, it was found that survival is
extended only three months for patients with advanced HCC after treatment with sorafenib
(Llovet et al., 2008). H19 has been suggested as a candidate tumor marker for HCC (Ariel et al.,
1998). Although diagnosis is an important step to treatment, it is more powerful to think of
directly targeting or using H19 in a gene therapy approach. DTA-H19 is a plasmid containing a
diphtheria toxin ‘A’ chain and expression is driven by the H19 promoter. Toxicity is highly
selective, because cancerous cells have been shown to activate the H19 promoter and normal
healthy cells do not. Current research has displayed a delay in tumor growth and tumor
regression of colon adenocarcinoma metastases in the livers of rat (Sorin et al., 2011), as well as
clinical trials for bladder and ovarian cancer by the company BioCancell (Jerusalem, Israel)
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(http://www.biocancell.com/lead-program/bc-819/). This indicates the potential for novel gene
therapies using lncRNAs, such as H19, promising new drug modalities.
Drug resistance is a major problem in chemotherapy. In the two examples regarding
chemotherapy drug metabolism and transport presented earlier, there is promise in targeting H19.
Often, MDR1 is overexpressed, leading to increased efflux of cancer drugs and inefficacy.
Targeting H19 in cancer therapy may reduce MDR1-associated drug resistance, as H19
knockdown has been shown to suppress MDR1 expression. Suppression is through increasing
MDR1 promoter methylation, leading to increased accumulation and efficacy/toxicity of
doxorubicin in doxorubicin-resistant R-HepG2 cells (Tsang and Kwok, 2007). The cisplatinresistant cell line A2780-DR cells also become chemosensitive with knockdown of H19 (Zheng
et al., 2016). These two examples are potentially important in the fight against drug resistance
and treating cancers.
1.5.7 Further Considerations at the H19 Locus, 91H and HOTS
Genes overlapping the H19 gene sequence with transcriptional activity have been
discovered other than H19’s well-studied microRNA, miR-675 (Figure 1.1). 91H and H19
opposite tumor suppressor (HOTS) are both antisense to H19 and have been discussed in the
context of disease. Their roles in liver have yet to be determined, leaving the door open for
further research. Due to their implication in other diseases, their sharing of sequence, and either
their similar regulation with or regulation of H19, it is important to discuss them here.
91H in human is a potentially 120 kb long transcript coded antisense to H19. At fulllength, it overlaps the entire H19 gene, the ICR between H19 and IGF2, and the previously
discussed enhancers that drive expression of H19 and IGF2 (Berteaux et al., 2008). Like H19,
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91H is also upregulated in a number of cancers (Berteaux et al., 2008; Deng et al., 2014; Gao et
al., 2015; Xia et al., 2016), and mirrors studies examining H19’s role as a tumor suppressor and
an oncogene with no clear consensus of the overall general mechanism. 91H is also important
for the regulation of IGF2 expression. Knockdown studies have shown that 91H contributes to
IGF2 expression at the paternal allele (Berteaux et al., 2008). 91H is also responsible for
maintaining H19/IGF2 imprinting and preventing DNA methylation at the H19/IGF2 locus (ICR
and H19 promoter) on the maternal allele, potentially by binding and masking these sites, driving
H19 and IGF2 expression (Vennin et al., 2016). Outside of controlling imprinting, 91H can also
directly activate a promoter of IGF2. This activation can be counteracted by H19 (Tran et al.,
2012). In order to develop future targets for therapies, it may be important to understand these
mechanisms of 91H that have a direct effect on H19 expression, as well as 91H’s role in normal
liver function, including its potential to cause liver disease.
HOTS is another gene transcribed from the H19 locus that overlaps all but the first exon,
first intron, and most of the second exon of H19 in human. HOTS is maternally expressed and
imprinted like H19, but unlike H19, it codes for a protein. When overexpressed, HOTS inhibits
various tumor types, and knockdown of HOTS results in tumor growth. In samples of Wilms
tumors, it was observed that a loss of imprinting at the locus that results in biallelic expression of
IGF2 also silences of HOTS. This led the authors to conclude that HOTS is a tumor suppressor
(Onyango and Feinberg, 2011). With little research on this transcript and its protein, it is
difficult to assume that it is a useful target in therapy. However, targeted overexpression or gene
therapy using HOTS may be useful to suppress cancer. As more information was discerned over
the years studying H19, its role in disease was discovered to be immensely complex. The same
could be true in further investigations of both 91H and HOTS.
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1.5.8 Conclusions
LncRNA research is a relatively new focus. Since H19 was one of the first lncRNAs to
be identified and characterized, there is an abundant amount of research depicting its various
roles. The epigenetic regulation of H19 is unique and complex, being an imprinted gene
containing a regulatory region that is differentially methylated depending on the parental origin.
H19 participates in normal liver functions, such as development, and its dysregulation occurs in
many liver disease, including HCC, type II DM, NAFLD, NASH, and cholestatic liver fibrosis.
LncRNAs, including H19, have unique regulatory abilities, capable of binding proteins. They
are also capable of participating in epigenetic modification of genes to affect gene expression in
numerous signaling pathways or are direct effectors of processes in normal function and disease.
Many mechanisms have been presented, indicating H19 is a complex actor with roles in many
organ systems, times of development, and in many disease states. Its complex role in HCC has
shown H19 to act as an oncogene regulating proliferation and angiogenesis while unusually also
acting as a tumor suppressor inhibiting metastasis. As the science progresses and gives us new
insights into how lncRNAs and H19 control normal liver function and disease, therapies to treat
disorders will follow eventually to improve overall human health.

Chapter 2: The Role of H19, a Long Non-coding RNA, in Mouse Liver Postnatal Growth
2.1 Introduction
Liver development requires both cell proliferation and differentiation. Cell proliferation
allows the liver to achieve its proper size in the body and cell differentiation allows the liver to
attain proper functions. Both of these events coincide concurrently during postnatal liver
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maturation. During this important, but understudied, phase of development, the liver undergoes
a switch in functions. In mouse, the liver becomes the major hematopoietic organ in the fetus
between embryonic days 10 to 15 (Zorn, 2008). After birth it matures into an organ primarily
functioning in metabolism (Hata et al., 2007). Throughout ontogenesis until the liver is fully
mature, changes occur in the expression profiles of many protein-coding genes involved in
important liver functions (Li et al., 2009a; Si-Tayeb et al., 2010), including the regulation of
energy metabolism (Renaud et al., 2014) and drug metabolism and transport (CollardeauFrachon and Scoazec, 2008; Cui et al., 2012; Peng et al., 2012; Lu et al., 2013; Peng et al.,
2013), which are responsible for important physiological functions of mature liver. However, it
is not fully understood what initiates this switch in functions.
Proteins involved in signaling pathways and regulation of splicing are implicated in
playing important roles in cell growth and differentiation during postnatal liver maturation.
Knockout of mouse liver β-catenin, the intracellular transducer in Wnt signaling, results in a
decrease in cell proliferation and a decrease in postnatal liver size (Apte et al., 2007). Yesassociated protein, the downstream effector of Hippo Kinase signaling, affects cell proliferation
and regulates genes controlling hepatic functions including metabolism of bile acids and retinoic
acids in mouse (Septer et al., 2012). Two splicing factors are also known to affect postnatal liver
maturation. Epithelial splicing regulatory protein 2 is induced in hepatocytes during the
postnatal age and controls the neonatal-to-adult switch of splice isoforms in gene transcripts
involved in proliferation and differentiation that control hepatocyte maturation in both mouse
and human (Bhate et al., 2015). Serine/arginine-rich splicing factor 3 (SRSF3) alters splicing of
genes that regulate glucose and lipid metabolism. Knockout of Srsf3 in mice results in a decline
in postnatal liver growth by a prolonged expression of fetal markers including persistence of
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hepatic hematopoiesis (Sen et al., 2013). Clearly, protein-coding genes are important for the
functional switch in developing liver, however, the role of non-coding genes has largely been
unexplored.
Long non-coding RNAs (lncRNAs) also change in identifiable expression patterns
throughout ontogenesis and potentially regulate liver development. Recently, our laboratory
examined the alterations of gene expression in lncRNAs during the liver’s functional transition
through the prenatal stage to adult life in mice (Peng et al., 2014). Three major ontogenic
expression patterns were found with specific lncRNAs enriched at the neonatal, adolescent, and
adult ages, indicating lncRNAs are developmentally regulated. Expression of lncRNAs with
their neighboring protein-coding genes was found to be correlated, indicating lncRNAs may
regulate the expression of nearby protein-coding genes or share regulatory regions within their
gene loci that coordinate their expression. LncRNA H19 was found to be most differentially
expressed lncRNA comparing prenatal expression to adult expression, and its cis protein-coding
partner, IGF2, an important fetal growth factor, exhibits a similar temporal expression pattern.
Despite being one of the most studied lncRNAs, H19’s role in liver development has not been
fully determined.
H19 is involved in normal liver physiology and is implicated in liver diseases (Pope et
al., 2017). H19 is expressed in liver during periods of increased cell proliferation, including liver
regeneration after injury (Pachnis et al., 1984) and hepatocellular carcinoma (Ariel et al., 1997;
Kim and Lee, 1997; Matouk et al., 2007). H19 is also highly expressed in fetal liver during
organogenesis. In a human fetal liver cell line, H19 expression inhibits cell proliferation through
Wnt signaling potentially to prevent overgrowth of fetal liver tissue (Wang et al., 2016a). We
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aim to test whether H19 plays a similar role in postnatal liver development, including both liver
growth and liver maturation, using an H19 knockout mouse model (Ripoche et al., 1997).
To test the effect of H19 on postnatal liver development, we used three genetically
different mouse groups. H19 is an imprinted gene uniquely expressed only from the maternal
allele (Bartolomei et al., 1991). Therefore, we carefully bred H19 knockout mice to generate
mice heterozygous for the null mutation strictly controlling which parental allele H19 is fully
intact or fully removed. Using wild type mice (H19+/+), H19 maternal allele knockouts (H19M/P+

), and H19 paternal allele knockouts (H19M+/P-), we were able to assess the role of H19 in

postnatal liver development when H19 is expressed or not expressed from a specific allele.

2.2 Materials and Methods
2.2.1 Animals
Eight-week-old C57BL/6 mouse breeding pairs were purchased from Jackson Laboratory
(Bar Harbor, ME). A permission for the use of previously characterized H19 knockout mice
(Ripoche et al., 1997) was received from Dr. Luisa Dandolo. A pair of H19 heterozygous male
knockout mice (male-H19+/-) were received from Dr. Linheng Li’s laboratory at the Stowers
Institute for Medical Research (Kansas City, MO, USA). Mice were housed according to the
animal care guidelines provided by the American Association for Animal Laboratory Sciences
and were bred under standard conditions in the Laboratory Animal Resources Facility at the
University of Connecticut (Protocol Number: A15-040). The use of these mice was approved by
the Institutional Animal Care and Use Committee, Office of Research Compliance. A breeding
scheme to generate paternal and maternal H19 knockout mice is illustrated in Figure 2.1. Male
heterozygous H19 knockout (H19+/-) mice (F-0) carrying the H19- on one allele with
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undetermined parental origin were initially bred with wild type (H19+/+) mice of the same
C57BL/6 background to generate F-1 male-H19+/- and female-H19+/- heterozygous. The F-1
female H19+/- were further bred with wild type mice to generate F-2 male and female maternal
H19 knockout (H19M-/P+) offspring and the F-1 male-H19+/- were further bred with wild type
mice to generate F-2 male and female paternal H19 knockout (H19M+/P-) offspring. F-2 wild type
(H19M+/P+) mice generated were used as controls. Liver samples were collected at the following
ages: day 5, 10 (neonatal), 15, 20, 30 (adolescent), and 60 (adult) after birth. Livers from both
males and females were collected for days 30 and 60 only, and livers from animals collected 30
days before birth were not considered sexually mature and not separated by sex. The livers were
immediately frozen in liquid nitrogen and stored at -80°C or fixed in formalin.

2.2.2 Human Liver Samples
Human liver samples were procured and RNA-sequencing performed by Dr. J. Steven
Leeder at Children’s Mercy Hospital (Kansas City, MO, USA). A total of 60 livers ranging in
age from before birth to 18 years after birth were analyzed for H19 and IGF2 expression.
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Figure 2.1. Breeding scheme diagram used to generate mice heterozygous for maternal and
paternal H19 knockout.
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2.2.3 Genotyping
Ear or tail snips were collected from mice for DNA extraction. PCR reactions were
performed for identification of H19 deletion using a REDExtract-N-Amp Tissue PCR Kit
purchased from Sigma-Aldrich (St. Louis, MO, USA). Primers were designed using a
PrimerQuest Tool from Integrated DNA Technologies (Coralville, IA, USA). Sequences for the
primers are forward 5’-CTGTTCATACTCCGTGGGATAG-3’, forward
CAGACATTCATCCCGGTTACTT-3’, reverse 5’-CCTACCCATTACGAGCCTTAC-3’, and
reverse 5’-GGGACCCATCTGTGTCTTGT-3’.

2.2.4 Reverse transcription polymerase chain reaction (RT-PCR)
Total RNAs were isolated from livers without gallbladders using TRIzol reagent from
Life Technologies (Guilford, CT, USA) according to the manufacturer's protocol. RNA
concentrations were determined using a Nano Drop spectrophotometer from Nano Drop
Technologies (Wilmington, DE, USA) at a wavelength of 260 nm. The integrity of the total
RNAs was evaluated on an Agilent 2200 Tape Station from Agilent Technologies (Santa Clara,
CA, USA). Gene expression at the RNA level of H19, miR-675-3p, miR-675-5p, IGF2, IGF1,
IGF1R, β-catenin, cyclin D1, CYP3A16, CYP3A11, CYP2B10, CYP2C29, and GAPDH was
determined by TaqMan assays from Life Technologies (Carlsbad, CA, USA) according to the
manufacturer's protocol. Data were analyzed by generation of cycling time (Ct) and delta Ct
(ΔCt) values for all genes against GAPDH.

2.2.5 Immunohistochemistry
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Fresh liver tissues were fixed in 10% buffered formalin, embedded in paraffin, and
sections were prepared and stained by the Connecticut Veterinary Medical Diagnostic
Laboratory at the University of Connecticut (Storrs, CT, USA). Immunohistochemistry was
performed using antibodies against Ki-67 (rabbit polyclonal, Cat. No. ab15580) and proliferating
cell nuclear antigen (PCNA) (rabbit polyclonal, Cat. No. ab18197) from Abcam (Cambridge,
UK). A secondary antibody conjugated to peroxidase allowed for color precipitation using a
VECTOR NovaRED Peroxidase (HRP) Substrate Kit from Vector Laboratories (Burlingame,
CA, USA). Images were captured using an EVOS XL Core Cell Imaging System from Thermo
Fisher Scientific (Waltham, MA, USA). Positively stained nuclei were identified by using the
ImageJ image processing program, version 1.50i, from National Institutes of Health (Bethesda,
MD, USA) using a color brightness threshold with a signal intensity greater than or equal to 200.

2.2.6 Western blotting
Total proteins in liver lysates were isolated in RIPA Buffer and protein concentrations
were determined by using a Qubit 2.0 Fluorometer by Invitrogen (Carlsbad, CA, USA) and the
Lowry protein assay from Bio-Rad (Hercules, CA, USA) with absorbance at 750 nm using a
Spectra MAX 190 from Molecular Devices (Sunnyvale, CA, USA). Proteins were run on
polyacrylamide gels using the Mini-PROTEAN Tetra System by Bio-Rad (Hercules, CA, USA)
and transferred onto PVDF membranes. Primary antibodies purchased from Cell Signaling
Technology (Danvers, MA, USA) include IGF1R (1:1000, rabbit polyclonal, Cat. No. 3027),
active β-catenin (1:1000, rabbit monoclonal, Cat. No. 8814), and total β-catenin (1:1000, rabbit
monoclonal, Cat. No. 8480), and albumin (1:1000, rabbit polyclonal, Cat. No. 4929). Primary
antibodies against Wnt6 (1:1000, rabbit polyclonal, Cat. No. ab50030) was purchased from
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Abcam (Cambridge, UK), α-fetoprotein (1:100, mouse monoclonal, Cat. No. MA5-12754) was
purchased from Thermo Fisher Scientific (Waltham, MA, USA), and GAPDH (1:3000, rabbit
polyclonal, Cat. No. G9545) was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Secondary antibodies, anti-rabbit IgG (1:1000, goat, Cat. No. 7074) and anti-mouse IgG (1:2000,
horse, Cat. No. 7076), were purchased from Cell Signaling Technology (Danvers, MA, USA).
Primary antibodies were conjugated to secondary antibodies conjugated to Horseradish
peroxidase for detection using a ChemiDoc MP Imaging System from Bio-Rad (Hercules, CA,
USA).

2.2.7 Statistical analysis
The data are shown as the mean ± standard deviation. The significance of differences
between means was determined using two-tailed unpaired Student’s t tests. Statistical analyses
were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La Jolla, CA, USA).
Differences were considered to be significant if p<0.05.

2.3 Results
2.3.1 Ontogenic expression of H19 and IGF2 in liver during postnatal maturation
Previously generated RNA-sequencing (RNA-Seq) data (Peng et al., 2014) were used to
examine H19 and IGF2 expression in wild type mouse liver (n = 36) at fetal, postnatal, and adult
ages (Figure 2.2). In mouse liver, H19 and IGF2 are highly expressed before birth and rise to
their highest level of expression around the time of birth. Expression levels precipitously decline
at a postnatal age (approximately 20 days after birth) to nearly undetectable levels. Adult mouse
liver does not express H19 or IGF2.
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Figure 2.2. Ontogenic expression of H19 and IGF2 in mice during postnatal maturation in
liver. Expression of H19 (A) and IGF2 (B) was determined by RNA-Seq in mouse livers at ages
-2, 0, 3, 5, 10, 15, 20, 30, 45, and 60 days after birth (n = 3 per group). Expression levels were
measured as FPKM (Fragments Per Kilobase of transcript per Million mapped reads). Values are
represented as mean ± S.D.
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Figure 2.3. Ontogenic expression of H19 and IGF2 in human during postnatal maturation
in liver. Expression of H19 (A) and IGF2 (B) was determined by RNA-Seq in human livers at
ages before birth, less than 1 year, 1 to 6 years, 6 to 12 years, and 12 to 18 years (n = 60).
Expression levels were measured as TPM (Transcripts Per Million). Values are represented as
mean ± S.D.
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2.3.2 Abolishment of expression of H19 and miR-675 in H19 knockout mice
Expression of H19 in livers of wild type, maternal H19 knockout, and paternal H19
knockout mice was determined by RT-PCR at ages of 5, 10, 15, 20, 30, and 60 days after birth
(Figure 2.4 A). In all ages examined, H19 was not expressed in mice when the gene knockout
was on the maternal allele despite the mice possessing an intact paternal allele (H19M-/P+). Wild
type mice (H19+/+) and heterozygous mice with H19 knockout on the paternal allele (H19M+/P-)
exhibited similar expression of H19 at all ages.

Two different conserved microRNAs, miR-675-3p and miR-675-5p, are produced from
the first exon of H19 (Dey et al., 2014). Using two different sets of primers directed against each
miR-675 variant, their expression was determined by RT-PCR (Figure 2.4 B). The pattern of
means for both miR-675-3p and miR-675-5p expression followed H19 expression. In most wild
type individuals, expression was high at early ages until approximately 20 days after birth when
levels precipitously decline. Certain wild type individuals, despite normally expressing H19 at
early ages, showed very little miR-675 expression, indicating large interindividual variation.
Similar to H19, miR-675 was only expressed when H19 was intact at the maternal allele
(H19M+/P+ and H19M+/P-) while knockout on the paternal allele (H19M+/P-) was inconsequential to
miR-675 expression. Essentially, H19 maternal allele knockout mice (H19M-/P+) are also miR675 knockout mice.

66

67

Figure 2.4. Expression of H19 and miR-675 RNA in mouse livers with H19 knockout on
different parental alleles. RNA expression of H19 (A) and miR-675-3p and miR-675-5p (B) in
mouse livers at ages 5, 10, 15, 20, 30, and 60 days after birth (n = 4 per group) was determined
by RT-PCR in wild type (H19M+/P+), maternal H19 knockout (H19M-/P+), and paternal H19
knockout (H19M+/P-) mice measured as fold-changes compared to the wild type. Values are
represented as mean ± S.D. * p<0.05, ** p<0.01, *** p<0.001.
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2.3.3 Changes of liver and body weights in the absence of H19 expression during postnatal
maturation
H19 impacts liver weight in the developing and adult male livers (Figure 2.5 A). Liver
weights are significantly higher only immediately after birth and in male adult mice not
expressing H19. Liver weights were significantly higher 5 days after birth in mice without H19
expression (p<0.01). No significant changes in liver weight were observed between wild type
mice and mice not expressing H19 for ages 10, 15, 20, or 30 days after birth. Adult males, but
not adult females, have significantly higher (p<0.001) liver weights when measured 60 days after
birth with H19 knockout on the maternal allele (H19M-/P+).

H19 impacts total body weight in developing and adult mice in both males and females
(Figure 2.5 B). Despite H19 expression not significantly affecting liver weight in adolescent or
adult female liver, body weights are significantly altered at both 30 (p<0.01) and 60 (p<0.001)
days after birth, affecting also the liver/body weight ratio significantly at 30 days after birth
(p<0.05). Male liver/body weight ratios are not significantly affected by H19 expression (Figure
2.5 C). H19 also controls body weights when the liver is developing. Body weights are
significantly higher with no H19 expression at 5 days after birth (p<0.001) and 20 days after
birth (p<0.05). Both males and females had significant (p<0.001) increases in body weight at 60
days after birth when H19 was not expressed. Females, but not males, were significantly heavier
at 30 days after birth (p<0.01) with no H19 expression through life.
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Figure 2.5. Liver and body weights for mice with H19 knockout on different paternal
alleles. Liver weights (A), body weights (B), and liver weight as a percentage of total body
weight (C) were measured at the time of liver harvest from mice ages 5, 10, 15, 20, 30, and 60
days after birth (n = 5-25). Values are represented as mean ± S.D. *p<0.05, **p <0.01,
***p<0.001.
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2.3.4 Changes in liver cell proliferation in the absence of H19 expression during postnatal
maturation
Corresponding data indicates liver weights are increased due to increases in cell
proliferation throughout mouse development when H19 is not expressed. Two markers of cell
proliferation, Ki-67 and PCNA, were used to measure proliferating cells in the tissue sections
(Figure 2.6). When stained for Ki-67, livers from H19 maternal allele knockouts (H19M-/P+)
show significantly more Ki-67 positive nuclei in livers of mice at ages 5 (p<0.001), 10
(p<0.001), 20 (p<0.001), 30 in both males and females (p<0.001), and 60 only in males
(p<0.001) days after birth. PCNA was also used to measure cell proliferation in an independent
experiment. These data closely resemble Ki-67 staining results, indicating livers without H19
expression proliferate more rapidly during development when compared to wild type. In the
maternal allele knockout mice, there were significantly more cells stained positive for PCNA at
ages 5 (p<0.001), 10 (p<0.001), and 20 (p<0.001) days after birth. Similar to Ki-67 results,
significant differences were observed through postnatal liver development until age 15 days after
birth, with significant differences again observed for age 20 days after birth. Discordant
measurements were observed between the two assays at ages 30 and 60 days after birth with Ki67 indicating significant changes for H19 maternal allele knockout mice (H19M-/P+) while PCNA
did not stain significantly different at either of these ages. Measurements for heterozygous
paternal allele H19 mutants (H19M+/P-) resemble wild type (H19+/+).
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Figure 2.6. Immunohistochemistry analysis for identification of proliferating cells in livers
of mice with H19 knockout on different paternal alleles. Livers were fixed in formalin,
embedded in paraffin, sectioned, and stained for (A) Ki67 or (B) PCNA for mice at ages 5, 10,
15, 20, 30, and 60 days after birth (n = 3 per group). A representative image was taken from mice
at age 20 days after birth. Arrows indicate cells stained positive for (A) Ki67 and (B) PCNA.
ImageJ software was used to count five sections per mouse. Values are represented as mean ±
S.D. ***p<0.001.
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2.3.5 Expression of IGF signaling and Wnt signaling genes in the absence of H19 expression
during postnatal maturation
Gene expression patterns for IGF2 and IGF1 were determined using RT-PCR for mice at
ages 5, 10, 15, 20, 30, and 60 days after birth (Figures 2.7 A and B, respectively). Both H19 and
IGF2 were highly expressed at early ages until 20 days after birth when expression precipitously
declines to undetectable levels and no expression persists through adult life. IGF1 exhibits the
opposite expression pattern, starting with low expression early in life, steadily increasing as the
liver develops. A significant increase (p<0.01) in IGF2 mRNA was found in H19 maternal allele
knockout mice (H19M-/P+) compared to wild type (H19+/+) at 20 days after birth, indicating H19
affects IGF2 expression. However, at all other ages measured, no significant differences were
found. IGF1 mRNA was not impacted by the absence of H19 expression.
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Figure 2.7. Expression of the fetal form IGF2 and adult form IGF1 RNA in mouse liver
with H19 knockout on different parental alleles. RNA expression was determined by RT-PCR
for (A) IGF2 and (B) IGF1 in mouse livers at ages 5, 10, 15, 20, 30, and 60 days after birth (n =
4 per group). Values are represented as mean ± S.D. **p<0.01.
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IGF1R expression was found to increase only at the protein level, but not at the mRNA
level in H19 maternal allele knockouts (H19M-/P+) compared to wild type (H19+/+). Although no
significant differences were observed in mRNA expression at all ages measured (Figure 2.8 A),
there was an increase in IGF1R protein expression when H19 was not expressed for each time
point measured (Figure 2.8 B). Levels of IGF1R protein expression were highly variable
between individuals at each age and experimental groups.
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Figure 2.8. Expression of IGF1R in mouse livers with H19 knockout on different parental
alleles. (A) RNA expression was determined by RT-PCR in mouse livers at ages 5, 10, 15, 20,
30, and 60 days after birth (n = 4 per group). (B) Protein expression was determined by Western
blot for IGF1R for mice at ages 5, 10, 15, 20, and 60 days after birth. Lanes 1-3 indicate wild
type (H19+/+) individuals and lanes 4-6 indicate H19M-/P+ individuals. Values are represented as
mean ± S.D.
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Wnt signaling was similarly only slightly impacted by the absence of H19 in mice. No
significant changes were observed at the mRNA level at all ages tested for either β-catenin or
cyclin D1 (Figures 2.9 A and B, respectively). Significant increases (p<0.05) were observed at
the protein level for active β-catenin in mice at age 5 days after birth and in total β-catenin in
mice at age 10 days after birth (Figure 2.9 C). Protein expression was also analyzed for the
ligand Wnt6, but no changes were observed.
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Figure 2.9. Expression of Wnt signaling in mouse livers with H19 knockout on different
parental alleles. RNA expression was determined by RT-PCR for (A) β-catenin and (B) cyclin
D1 in mouse livers at ages 5, 10, 15, 20, 30, and 60 days after birth (n = 4 per group). (C)
Protein expression was determined by western blot for Wnt6, active β-catenin, and total βcatenin for mice at ages 5, 10, and 15 days after birth (n = 2 per group). Values are represented
as mean ± S.D. *p<0.05.
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Chapter 3: The Role of H19, a Long Non-coding RNA, in Mouse Liver Postnatal
Maturation

3.1 Expression of P450 drug metabolizing enzymes in the absence of H19 expression during
postnatal maturation
Gene expression was determined for P450 enzymes in H19 paternal allele (H19M+/P-),
H19 maternal allele knockouts (H19M-/P+), and wild type mice (H19+/+). There were no
significant differences in RNA expression for CYP3A16 (Figure 3.1 A) or CYP3A11 (Figure 3.1
B). A significant increase (p<0.05) was found in CYP2B10 in H19 maternal allele mutants
(H19M-/P+) compared to wild type (H19+/+) for male mice aged 30 days (Figure 3.1 C).
Significance was not found in females aged 30 days or at any other ages measured for CYP2B10.
CYP2C29 expression is delayed in mice when H19 expression is not present early in life (Figure
3.1 D). A significant decrease (p<0.05) was detected at 15 days after birth in H19 maternal allele
mutants (H19M-/P+). Normally, as seen in wild type (H19+/+) and in paternal H19 allele
knockouts (H19M+/P-), CYP2C29 begins to be slightly expressed at 15 days after birth. However,
when H19 is not expressed, CYP2C29 is not expressed until later in development and resumes its
full normal expression at 20 days after birth.
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Figure 3.1. Expression of P450 drug metabolizing enzymes in mouse livers with H19
knockout on different parental alleles. RNA expression was determined by RT-PCR for (A)
CYP3A16, (B) CYP3A11, (C) CYP2B10, and (D) CYP2C29 RNA in mouse livers at ages 5, 10,
15, 20, 30, and 60 days after birth (n = 4 per group). Values are represented as mean ± S.D.
*p<0.05.
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3.2 Expression of α-fetoprotein and albumin protein in the absence of H19 expression
during postnatal maturation
Liver postnatal protein expression for α-fetoprotein was examined in mice at ages
corresponding to the decline of expression of H19 in normal wild type mice. No significant
differences in α-fetoprotein were observed between H19 maternal allele knockouts (H19M-/P+)
and wild type (H19+/+) (Figure 3.2 A). In mice aged 20 days after birth, no α-fetoprotein protein
expression was found in liver for either test group. As observed in IGF1R protein expression,
large interindividual differences were found between the three mice tested in each group.

Liver postnatal protein expression for albumin was examined in mice at the early ages of
development. Western blots indicate no significant difference in protein expression of albumin
in livers of mice at ages 5 or 10 days after birth (Figure 3.2 B) for either test group. As with αfetoprotein, there were large interindividual differences.

87

88

Figure 3.2. Protein expression of α-fetoprotein and albumin in mouse livers with H19
knockout on the maternal allele. Protein expression was determined by Western blot for (A) αfetoprotein in mouse livers ages 15 and 20 days after birth, and (B) albumin in mouse livers ages
5 and 10 days after birth. Lanes 1-3 indicate wild type (H19+/+) individuals and lanes 4-6
indicate H19M-/P+ individuals. Values are represented as mean ± S.D.
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Chapter 4: Summary
4.1 Discussion
Research on H19 in normal liver development has primarily focused on fetal
development with little regard to H19’s role after birth despite this being a time when the liver is
continually growing and is dynamically changing its function from being a hematopoietic organ
to a metabolic organ. When discovered, Pachnis et al. initially characterized H19 expression in
mouse from before birth through the postnatal age until expression is terminated, by their
observation, around 28 days after birth (Pachnis et al., 1984). We have recapitulated their initial
temporal expression pattern using modern techniques and expanded upon their seminal
observations with a focus on H19’s role in postnatal liver maturation, including both liver growth
and changes in the liver’s ability to achieve adult liver function.
Liver growth is accelerated early in postnatal liver development when H19 is not
expressed. The overgrowth phenotype has been previously characterized for mice inheriting the
H19-null allele from their mother (Leighton et al., 1995a). Mice used in this study that were
heterozygous containing a functional maternal allele but with a mutated paternal allele resemble
homozygous wild type mice throughout our observations, as the paternal allele was
inconsequential to H19 expression. We observed the overgrowth phenotype by measuring both
the total body and liver weights through the postnatal ages. Early in life, liver weights are
significantly affected when H19 is not expressed (Figure 2.5 A). Coordinately, we also
measured the level of cell proliferation in liver and found significant changes in positively
stained nuclei for two different cell proliferation markers, indicating enhanced proliferation that
persists through many measured postnatal ages (Figure 2.6). Ki-67 is preferentially expressed
during late G1, S, G2, and M phases of the cell cycle, but not in the resting G0 phase (Scholzen
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and Gerdes, 2000). PCNA is an accessory protein for DNA polymerase alpha required for DNA
synthesis, and is elevated during the G1/S phase of the cell cycle (Kelman, 1997). Both markers
indicate that the absence of H19 expression enhances cell proliferation in the developing mouse
livers.
Increases in cell proliferation do not directly result in increases in liver mass. There is a
discordance with observations in significant liver weight increases and increases in the markers
indicating cell proliferation in H19 maternal allele knockout mice. Liver weights are only
significantly increased immediately in early life and in adult males while increases in
proliferation are observed throughout most of liver development at postnatal ages. Interestingly,
both markers indicate no significant increases in cell proliferation at 15 days after birth despite
showing significant increases before and after this age in the absence of H19 expression,
suggesting H19 does not influence proliferation at this specific time of development.
Loss-of-function of H19 in developing mice induces changes in liver that persist even at
ages when H19 is not normally expressed (ages 30 and 60 days after birth). An increase in adult
male liver weight can be explained by the accumulation of organ mass at earlier ages too subtle
to have been detected at prior ages. Increases in proliferation as observed by Ki-67 at ages 30
and 60 days after birth in H19 maternal allele knockout mice may be the result of more complex
pathway changes that are initiated at the time of normal H19 expression and persist after H19 is
no longer expressed. These late age changes were not observed in the PCNA stain (Figure 2.6
B).
We then sought to determine how the loss of H19 expression results in an increase in
liver mass and an increase in proliferating cells throughout postnatal development by first
examining IGF signaling. There is a strong correlation in expression patterns between lncRNAs
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and protein coding genes within the same loci, suggesting cis regulation with the lncRNA
potentially influencing its protein coding partner (Peng et al., 2014). Others have shown that
regulation is not always the lncRNA acting directly on the protein coding gene, but rather its
promoter or nearby regulatory regions that influence gene expression of nearby genes (Engreitz
et al., 2016). H19 and Igf2 reside next to each other on chromosome 7 in the mouse and have
similar temporal expression patterns in postnatal liver. Different H19-null mouse models have
been used to determine the function of not only H19 RNA, but also regulatory sequences
surrounding its locus. Some mouse models have deletions that span into the Imprinting Control
Region (ICR) between H19 and Igf2 resulting in disruption of imprinting of Igf2, which authors
have concluded leads to biallelic expression of IGF2 and the overgrowth phenotype (Leighton et
al., 1995a). However, our model has only H19 and a portion of its promoter containing an Sp1
site and TATA box removed, leaving the ICR intact allowing us to study only the effects of H19
on postnatal liver development (Ripoche et al., 1997). Our results demonstrate that deletion of
the ICR, causing bialleleic expression of IGF2, is not needed to induce the overgrowth
phenotype.
Our measurements indicate H19 has a minimal effect on IGF2 expression, with
significant increases in IGF2 expression observed only at 20 days after birth (Figure 2.7 A).
However, at 5 days after birth, the liver overgrowth phenotype is observed (Figure 2.5 A), and
cellular proliferation is significantly increased (Figure 2.6) throughout most postnatal ages when
H19 is not expressed. This indicates other pathways may be affected by the H19 loss-offunction.
The Wnt signaling pathway has been shown to be important in the development of many
different tissue types and organs. The canonical intracellular transducer, β-catenin, is activated
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after the Wnt ligand binds to a Frizzled family receptor. This activation causes β-catenin
accumulation in the cytoplasm and its eventual localization into the nucleus where it acts as a
coactivator of transcription factors, affecting gene transcription (Rao and Kuhl, 2010). Cyclin
D1, a cell cycle inducer important for the G1 to S phase transition, is a target for regulation by βcatenin (Tetsu and McCormick, 1999) in many different physiological processes including liver
growth (Monga, 2014). Wnt signaling has been shown to be inhibited by H19 in fetal liver
leading to inhibition of cell proliferation (Wang et al., 2016b), and Wnt signaling influences
proliferation in liver at postnatal ages (Apte et al., 2007). No significant changes were observed
at the mRNA level for either β-catenin or a downstream gene target of the pathway important for
cellular proliferation, cyclin D1, when H19 is not expressed (Figure 2.9). Protein expression was
also analyzed for the Wnt ligand and both activated β-catenin and total β-catenin. Antibody
detection against Wnt6 was chosen due to Wnt6 being involved in canonical signaling and its
high expression in developing tissues (Zeng et al., 2007). No significant changes were observed
in Wnt6 expression, indicating Wnt signaling was affected only downstream in the pathway.
Significant differences were discovered at the protein level in early life (age 5 days after birth)
for active β-catenin, and total β-catenin is also significantly higher at 10 days after birth
indicating similar results as observed in prior studies examining fetal H19 inhibition of β-catenin
protein (Wang et al., 2016b). It is not surprising significant changes were not observed at the
RNA level for genes within the canonical pathway. However, mRNA expression for cyclin D1,
which is a direct target of Wnt signaling at the transcriptional level, was not found to be
significantly altered.
H19 encodes a microRNA, miR-675, within its first exon (Cai and Cullen, 2007). H19
knockout on the maternal allele abolishes expression of both H19 and miR-675 despite the status
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of the paternal allele (Figure 2.4). H19 potentially impacts liver growth and proliferation
through the action of miR-675. Prior literature has shown proper processing of miR-675 can
slow growth in the placenta, and increases of miR-675 downregulate IGF1R, which causes IGF
signaling to be inhibited (Keniry et al., 2012). Consistent with our data, removal of H19
expression only causes a significant increase (Figure 2.7 A) in IGF2 at 20 days after birth despite
detection of increased liver weights and cell proliferation at earlier ages. This suggests
involvement of another regulator. Although we have found differences in liver development at
postnatal ages compared to fetal liver development, inhibition of IGF1R by miR-675 may be the
mechanism by which H19 controls liver growth. IGF1R expression was examined at both the
RNA and the protein levels. No significant differences were found, but a trend of an increase in
IGF1R expression at the protein level was found for each age measured, suggesting a loss of
miR-675 expression may be the cause for the overgrowth phenotype and the increase in cell
proliferation.
Developmental P450 expression pattern for Cyp3a is not influenced by H19 expression.
The CYP3A family undergoes a switch in dominant isoforms during postnatal liver
development. Early in life, CYP3A16 is the dominant isoform in mice. The adult CYP3A
isoform switches to predominantly CYP3A11 around 20 days after birth (Li et al., 2009b).
Despite this developmental shift pointing to CYP3A potentially being impacted by H19
expression, no significant differences were observed between wild type mice and mice with the
maternal H19 allele knocked out (Figures 3.1 A and B).
However, H19 does affect the expression of P450 enzymes CYP2B10 and CYP2C29 at
particular points during mouse liver development. Sex differences in CYP2B10 expression are
known between wild type males and females. Wild type adult females are known to display a
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higher expression level than adult males in mouse liver (Renaud et al., 2011). Our results also
point to a sex difference in H19’s role affecting the development of CYP2B10 only significantly
in male mice and not female mice at 30 days after birth (Figure 3.1 C). CYP2C29 is not
normally expressed until the liver begins to mature. In wild type mice, slight expression is
observed at 15 days after birth. In H19 maternal allele knockouts with no H19 expression, the
expression of CYP2C29 only begins to be detected at 20 days after birth, and at 15 days after
birth is not expressed and significantly (p<0.05) lower compared to wild type mice (Figure 3.1
D). Despite these specific changes, P450s were largely found to be unaffected by H19
expression indicating H19 may not be important for liver maturation.
Insignificant changes in expression patterns of albumin and α-fetoprotein, two
developmentally regulated genes, also indicate H19 may not be important for liver maturation.
Albumin production is a function and marker of normal mature hepatocytes, but can be detected
in nascent hepatic cells (Cascio and Zaret, 1991). Albumin production rises continually
throughout liver development and is at maximum in adult liver (Jochheim et al., 2004). Due to
this expression pattern, we chose the two earliest ages in our study (5 and 10 days after birth) to
examine changes in albumin production in developing liver in mice with and without H19
expression. If H19 affects the maturation of liver, a difference in levels of albumin production
might be noticed at different developmental ages. Conversely, α-fetoprotein is a fetal liver gene
and the major plasma protein present in the fetus. The RNA expression profile of α-fetoprotein
in postnatal liver development resembles H19, with highest expression early in life and a
dramatic decline after birth. Expression of α-fetoprotein mRNA declines to undetectable levels
around 14 days after birth in mouse (Pachnis et al., 1984). Due to this pattern, we chose to
examine protein expression of α-fetoprotein at ages 15 and 20 days after birth between wild type
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mice and mice not expressing H19. Protein expression was still detected at 15 days after birth in
both groups, but by 20 days after birth, α-fetoprotein protein was not observed for either test
groups (Figure 3.2 A). No significant changes were observed in the production of albumin or αfetoprotein when H19 is not expressed (Figure 3.2) indicating H19 may not control these
developmentally regulated genes.
H19’s role in postnatal liver maturation appears to be consistent with its role in other
contexts. H19 is expressed in highly proliferating tissues including fetal and postnatal livers
(Pachnis et al., 1984), and H19 expression can reemerge in adult liver during hepatocellular
carcinoma (Kim and Lee, 1997; Matouk et al., 2007), or during regeneration after injury (Pachnis
et al., 1984; Yamamoto et al., 2004). Despite its expression in proliferating tissue, our data
support the hypothesis that normal expression or reemergence of H19 is to limit cellular
proliferation to control overgrowth. H19 may be falsely implicated in promoting cell growth if
basic correlations linking proliferation and H19 expression are made without mechanistic
examination of H19’s actual molecular role.

4.2 Conclusions
H19 affects liver growth controlling proliferation through IGF and Wnt signaling, but
may be inconsequential to liver maturation during postnatal development. H19’s action is
potentially through miR-675. miR-675 has been shown to inhibit IGF1R indicating uninhibited
IGF signaling may be the cause of the overgrowth phenotype and increases in cell proliferation.
Despite H19’s regulation of liver growth, evidence suggests H19 may not play a significant role
in postnatal liver maturation. Albumin and α-fetoprotein expression patterns were not
significantly altered, and P450 expression pattern changes were only affected at specific ages.
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